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Abstract 
Pancreatic cancer is one of the most fatal malignancies in the world with an 
overall 5-year survival rate of less than 5%. Diagnosing pancreatic cancer is 
not always straightforward. Clinical imaging of the pancreas can be 
misleading and currently available clinical biomarkers are few and lack 
sensitivity and specificity. Obtaining tissue or cytology from the 
pancreaticobiliary system to confirm a diagnosis is clinically invasive and 
may be inconclusive. Further non-invasive diagnostic biomarkers are clearly 
required. I describe the feasibility of nuclear magnetic resonance (NMR) 
spectroscopy as a modality for novel plasma and urine pancreaticobiliary 
biomarker discovery 
Plasma and urine samples from 44 patients undergoing pancreatic resection 
for pancreaticobiliary malignancy along with a benign cohort of 45 patients 
were acquired. Spectra were obtained on a Varian NMR 500 MHz 
spectrometer. Unsupervised and supervised multivariate pattern recognition 
techniques were used for chemometric analysis. Model validation was 
assessed through permutation and cross validation techniques 
Plasma metabonomic profiling identified clear separation between malignant 
and benign pancreaticobiliary disease with an overall sensitivity and 
specificity of 64.9 and 73.5% respectively. Sensitivity and specificity among 
non-jaundiced patients rose to 75 and 75.8% respectively. Suppressed 
metabolites among cancer patients included VLDL, valine and acetate. Up-
regulated metabolites included isobutyrate, 3-hydroxybutyrate, lactate, 
acetoacetate, pyruvate, glucose and taurine. Urinary metabonomic profiling 
failed to satisfactorily discriminate between benign and malignant disease.  
Plasma nuclear magnetic resonance metabonomic profiling has significant 
potential for future pancreaticobiliary biomarker development. Plasma 
bilirubin is an important confounding factor, which must be accounted for in 
all future pancreaticobiliry metabonomic studies 
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1 Introduction 
1.1 Pancreatic cancer 
1.1.1 Disease burden on society 
Pancreatic cancer (PC) is one of the most fatal malignancies in the world. 
The overall 5-year survival rate of less than 5% is the lowest of the 21 most-
common malignancies in the UK. Around 70,000 new cases of PC are 
diagnosed each year in the European Union with around 8000 occurring in 
the UK. PC is the fourth most common cause of cancer related death in men 
(after lung, prostate and colorectal) and women (after lung, breast and 
colorectal) within the UK (1). The lifetime risk of developing PC is 1 in 77 for 
men and 1 in 79 for women (2). The incidence of PC increases with age with 
around three-quarters of cases occurring in the over 65 (3). The poor 
prognosis is due to several factors including delayed presentation, high 
metastatic potential and resistance to chemoradiotherapy. The early 
presenting features of PC are difficult to recognize and are vague and non-
specific. As such 80% of cases are advanced and non-operable at 
presentation (4). Although surgical resection offers the only chance for long-
term survival patients rarely survive beyond five-years. The median survival 
following surgery is 11-20 months with five-year survival ranging from 7-25% 
(5, 6). Patients with irresectable locally advanced disease have a median 
survival of 6-11 months. Patients who have metastatic disease have a 
median survival of only 2 - 6 months (7, 8).  
1.1.2 Pancreatic cancer current diagnostic limitations 
Following the clinical suspicion of PC, imaging modalities such as trans-
abdominal ultrasound (TA USS), endoscopic ultrasound (EUS), computed 
tomography (CT) or endoscopic retrograde cholangiopancreatography 
(ERCP) may be deployed. TA USS is often the first investigation in a 
jaundiced patient in the UK. Common bile duct dilation (> 7mm, 10mm in 
patients post cholecystectomy) together with pancreatic duct dilation (> 
2mm) is an indirect sign of a pancreatic head lesion (double-duct sign). TA 
USS is however operator dependent and limited by overlying bowel gas and 
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patient habitus (9). CT is the most widely available and best-validated 
imaging modality for diagnosing and staging patients with pancreatic cancer. 
A pancreas CT protocol involves triphasic (arterial phase, late arterial phase, 
and venous phase) cross-sectional imaging. The triphasic CT protocol allows 
for selective visualization of important arterial (celiac axis, superior 
mesenteric and peri-pancreatic arteries) and venous structures (superior 
mesenteric, splenic, and portal vein), thereby providing an assessment of 
vascular invasion by the tumour (10). Positron emission computered 
tomography (PET/CT) may be used to assess for metastatic disease. In a 
retrospective study the sensitivity of detecting metastatic disease for PET/CT 
alone, standard CT alone, and the combination of PET/CT and standard CT 
was 61%, 57%, and 87%, respectively (11). EUS was introduced in the 
1980‟s to overcome difficulties in visualization of the pancreas on TA USS. 
EUS may also be used to guide tissue collection for cytological or histological 
analysis (12). The diagnostic accuracy of fine needle aspiration at EUS is 
around 71%. The diagnostic yield of cytology from common bile duct 
brushings at ERCP lies between 23 and 41% (13, 14).  
Although pancreatic ductal adenocarcinoma (PDA) accounts for 90% of 
exocrine PC additional cell lines include adenosquamous, colloid, hepatoid, 
medullary, signet ring and undifferentiated carcinoma. Identifying these cell 
lines pre-operatively is difficult but potentially advantageous due to their 
varying clinical characteristics (prognosis and chemosensitivity). Colloid 
carcinomas often arise within type 1 intra-ductal papillary-mucinous 
neoplasms and have an improved five year survival of 57% following 
resection (15, 16). The prognosis from adenosquamous, hepatoid, medullary 
and undifferentiated tumors is worse than that of PDA (17-21).  
1.1.3 Chemotherapy for pancreatic cancer 
PC is highly desmoplastic with prominent stroma (22). The stromal 
compartment plays an active role in promoting invasion and growth of PC 
and is a physical barrier for drug delivery and chemoresistance (23). As such 
adjuvant chemotherapy following surgery is associated with only a modest 
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improvement in overall survival. In the European Study Group for Pancreatic 
Cancer-1 (ESPAC-1) trial adjuvant chemotherapy improved survival from a 
median of 14 with observation alone to only 19.7 months (p = 0.0005) (24). It 
has been suggested that neoadjuvant therapy has no added advantage in 
terms of surgical resectability or survival among patients presenting with 
resectable tumours (25). Advantages of neoadjuvant therapy include 
facilitating negative margin resection among those with borderline resectable 
disease. Neoadjuvant therapy may in addition highlight aggressive tumour 
types (with disease progression during chemotherapy) for which surgery is 
avoided (25, 26). For metastatic disease gemcitabine has historically been 
the agent of choice. In 2010 the phase II/III PRODIGE 4/ACCORD 11 trial 
was instrumental in changing perceptions towards palliative chemotherapy. 
Patients were randomly assigned to FOLFIRINOX (oxaliplatin, leucovorin, 
irinotecan and fluorouracil bolus followed by infusional fluorouracil) or 
gemcitabine alone. Median overall survival was substantially longer on the 
FOLFIRINOX arm (11.1 month vs. 6.8 months; p < 0.001) (27).  
1.2 Precursors to pancreatic cancer 
PDA is believed to arise from precursor lesions that develop into invasive 
carcinoma through a multistep carcinogenic process. This process is known 
to take at least 10-years (28). This provides a large window of opportunity for 
screening among the high-risk population.  In a study by Biankin et al. an 
average of 26 mutations per-patient were identified among a cohort of 142 
PC patients who collectively displayed 2,016 non-silent mutations (29).  
 
The most common pre-neoplastic lesion seen histologically among 80% of 
patients with PDA is pancreatic intraepithelial neoplasia (PanIN) (30). PanIN 
may arise within regions of acinar-to-ductal metaplasia (31). PanIN may be 
classified as PanIN1A, PanIN1B, PanIN2 and PanIN3 depending on the 
grade of architectural and nuclear atypia (32). PanIN3 lesions represent 
carcinoma in-situ and may harbour mitotic figures and exhibit local invasion.  
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1.3 Pancreatic cancer screening & the high risk population 
There is no current evidence to support screening the population as a whole 
as the overall risks (in terms of diagnostic intervention) would out-weigh the 
potential benefits (33). Screening is however of potential benefit to a higher 
risk population with a lifetime risk of over 5% and/or relative risk greater than 
five-fold of developing PC (34).  The international cancer of the pancreas 
screening (CAPS) group has defined „„successful screening” as the detection 
and treatment of T1N0M0 margin negative pancreatic cancer and high-grade 
dysplastic precursor lesions including pancreatic intraepithelial neoplasia-3 
(PanIN-3), intraductal papillary mucinous neoplasm (IPMN) with high-grade 
dysplasia, and mucinous cystic neoplasm (MCN) with high-grade dysplasia 
(34).  
1.3.1 Risk factors for pancreatic cancer 
1.3.1.1 Generic risk 
Smoking is estimated to be the cause of 25-30% of PC cases in the UK (35). 
Current cigarette smokers and former smokers who have quit for less than 5-
years have a higher risk of pancreatic cancer than non-smokers (odds ratio: 
1:71 and 1:78 respectively) (36). Overweight and obese individuals have an 
increased risk (odds ratio: 1.8 and 1.22 for males and females, respectively) 
(37). Patients with diabetes are at higher risk for PC (odds ratio: 1:76) (38) . 
New onset of diabetes may also be an early indicator of PC (39). Diets rich in 
red meat and dairy are associated with an increased cancer risk (40) along 
with exposure to ionizing radiation, insecticides, nickel, acrylamide, 
halogenated hydrocarbons and chlorinated hydrocarbon solvents (41-43). 
Chronic pancreatitis is associated with a 7.2 fold increased risk (44).  
1.3.1.2 Genetic risk 
It is estimated that 10% of patients suffering from PC have a hereditary 
component to their disease (45, 46). Peutz-Jager‟s (PJ), familial atypical 
multiple mole melanoma (FAMMM), familial breast and ovarian cancer 
syndrome, hereditary non-polyposis colorectal cancer (HNPCC), hereditary 
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pancreatitis and familial pancreatic cancer (FPC) are all syndromes which 
are known to predispose to PC. PJ is an autosomal dominant syndrome 
characterised by a STK11 gene mutation (47). The cumulative lifetime risk of 
PC among these patients is 36% (48). FAMMM is an autosomal dominant 
syndrome with variable penetrance developing following p16/CDKN2A gene 
mutation (49). Patients with FAMMM suffer from multiple benign melanocytic 
nevi, dysplastic nevi and melanoma (50). The lifetime risk of developing PC 
is increased 13-22 fold among these patients (51, 52).  Familial breast and 
ovarian cancer syndrome is an autosomal dominant syndrome due to 
germline mutation in either the BRCA1 and/or BRCA2 gene. Mutation 
carriers are at a higher risk of developing breast, ovarian, gastrointestinal 
and prostatic cancer (53, 54). The risk of developing PC is increased 3-10 
fold among BRCA2 and 2.3-3.6 fold among those carrying the BRACA1 
mutation (54). HNPCC occurring due to mismatch repair gene (MLH1, MSH2, 
MSH6 and PMS2) mutation is characterized by early-onset colorectal and 
extra-colonic malignancy (55) including an 8.6 fold increase in the risk of 
developing PC (56). Hereditary pancreatitis is a rare inherited autosomal 
dominant disorder with incomplete penetrance (57). The lifetime risk of 
developing PC is 40% among these patients (58). (58). FPC describes 
families with at least two first-degree relatives with confirmed exocrine PC 
that do not fulfil the criteria of other inherited tumour syndromes (59, 60).  
1.3.1.3 Pancreatic cystic lesions 
As a result of the widespread use of cross-sectional imaging, pancreatic 
cystic lesions are being discovered in increasing frequency (61). In an Italian 
study pancreatic cystic lesions were identified on 1.2% of 24,039 MRI or CT 
scans arranged for alternative pathology (62). The vast majority of lesions 
are asymptomatic. Pancreatic cystic lesions may rarely present with pain, 
exocrine insufficiency or obstructive jaundice (63). Accurate classification of 
the cystic lesion is imperative due to the potential for malignant change 
among specific lesions. This is often challenging and may be incorrect in up-
to a third of cases (64). The most commonly recognised lesions are serous 
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cystic neoplasms, mucinous cystic neoplasms and intraductal papillary 
mucinous neoplasms.  
1.3.1.3.1 Serous cystic neoplasms (SCN’s)  
SCN‟s account for 20-30% of all diagnosed pancreatic cystic tumours. SCN‟s 
occur most commonly in women with a peak incidence in those over 70 
years old (65). Malignant transformation is rare (66). SCN‟s may be micro or 
macrocystic. Macrocystic lesions consist of unilocular or bilocular cysts 
greater than 2 cm in diameter, which can be difficult to differentiate from 
either mucinous cystic neoplasms or pancreatic pseudocysts. SCN‟s do not 
communicate with the pancreatic duct and have a honeycomb appearance 
on CT with a central area of calcification (65). Although the presence of 
glycogen containing cells on cytological examination of EUS cyst fluid is 
diagnostic, negative cytology does not exclude a diagnosis. Cytology alone 
correctly identifies only 38% of SCN‟s (67). A fluid amylase level of <250 U/L 
along with an absent history of pancreatitis may be used to distinguish 
pseudocysts and non-pseudocysts with a sensitivity and specificity of 44% 
and 98% respectively (67). Due to the low risk of malignant potential SCN‟s 
are often managed non-operatively (68) . Up to 10% of SCN‟s are mistaken 
for solid tumours such as neuroendocrine or solid pseudopapillary (69). 
1.3.1.3.2 Mucinous cystic neoplasms (MCN’S)  
MCN‟s occur mainly in women with a peak incidence in the fifth decade of life 
(65). Up-to 17.5% of MCN‟s (in contrast to SCN‟s) undergo malignant 
transformation (70). Findings on cross sectional imaging are that of a large 
unilocular cyst with peripheral calcification.  MCN‟s do not communicate with 
the main pancreatic duct and occur predominantly within the body or tail of 
the pancreas. One pathogenic feature of MCN‟s along with IPMN‟s (also 
potentially pre-malignant) is the presence of mucin containing goblet cells at 
cytological examination. To improve diagnostic accuracy cyst 
carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) 
may be measured. CEA glycoprotein is secreted by the epithelium of 
mucinous but not serous pancreatic cysts (71). CEA however is of little use 
  
7 
 
in differentiating a mucinous lesion with dysplastic or malignant change from 
a benign mucinous cyst (72, 73). Due to the high incidence of invasive 
carcinoma within MCN‟s surgical resection for all patients who are medically 
fit is recommended (74).  
1.3.1.3.3 Intraductal papillary mucinous neoplasms (IPMN’s)  
IPMN‟s occur predominantly in males most commonly in their seventh 
decade of life (75). In contrast to MCN‟s they communicate with either the 
main pancreatic duct or its side branch (76). Invasive carcinoma occurs in 
up-to 50% of main duct IPMN‟s versus 11% of branch duct IPMN‟s (77). On 
cross sectional imaging dilatation of either the main pancreatic duct or its 
side branch is typically seen (76). Surgical resection is recommended for all 
otherwise fit patients with main duct IPMN‟s (74). The 2012 consensus 
guidelines only recommended surgical treatment in patients with branch duct 
IPMN when one of the following are present: lesion >3 cm, mural nodules, 
main pancreatic duct dilatation  >6 mm, symptomatic lesions or positive 
cytology (74).  
1.4 Biomarkers & pancreatic cancer 
For the reasons described above biomarkers are of crucial importance in the 
recognition and treatment of patients with suspected PC. A biomarker 
(biological marker), as defined by the National Institutes of Health Biomarker 
Working Group is a characteristic that is objectively measured and evaluated 
as an indicator of a normal biological process, pathogenic processes, or a 
pharmacologic response to a therapeutic intervention (15). A biomarker may 
be diagnostic, prognostic or predictive. The ideal diagnostic biomarker would 
be non-invasive, inexpensive, and potentially an effective screening test to 
identify high-risk premalignant lesions or early invasive cancers at a curable 
stage. Effective tests require a high degree of sensitivity and specificity to 
minimize unnecessary interventions for false positive results. Prognostic 
markers predict the natural history of disease. Predictive markers facilitate 
personalized treatment as they may be used to predict a response to a 
particular therapy such as chemotherapy (78). 
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1.4.1 Currently available biomarkers 
1.4.1.1 Carcinoembryonic antigen 
The glycoprotein carcinoembryonic antigen (CEA) which is used clinically as 
a biomarker for colorectal cancer was discovered in 1965 and was the first 
biomarker for PC (79). CEA has a sensitivity and specificity of 54% and 79% 
respectively for detecting PC. Low sensitivity along with known elevation in 
breast, gastric and colorectal cancer limit its use for PC diagnosis (80).  
1.4.1.2 Carbohydrate antigen 19-9 
The serum carbohydrate antigen 19-9 (CA 19-9) is the only biomarker for PC 
in routine clinical use today. CA 19-9 was first described in the colorectal 
cancer cell line SW1116 in 1979 (81). CA 19-9, also known as sialyl Lewis-a 
is a glycolipid expressed on the surface of cancer cells. CA 19-9 is derived 
during aberrant production of disialyl Lewis-a, which acts as a ligand for 
monocytes and macrophages (82).  
1.4.1.2.1 Serum CA 19-9 as a diagnostic marker 
In order to evaluate the utility of CA 19-9 in screening an asymptomatic 
population Kim et al. assessed CA 19-9 serum levels among 70,940 
asymptomatic individuals. Among 1,063 individuals with an elevated CA 19-9 
(> 37 U/ml) only 4 patients with PC were identified. Although sensitivity and 
specificity were 100 and 98.5% respectively, the positive predictive value of 
the test was only 0.9% (83). Routine serum CA 19-9 is therefore a poor test 
for screening an asymptomatic population. 
 
The utility of serum CA 19-9 as a diagnostic biomarker significantly improves 
when deployed among a symptomatic patient cohort or a cohort presenting 
with a pancreatic mass. In a systematic review of 26 case-series (including a 
total of 2,283 symptomatic patients) Goonentilleke et al. described a 
sensitivity and specificity of 79 and 82% respectively along with positive and 
negative predictive values of 72 and 81% respectively (84). 
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1.4.1.2.2 Serum CA 19-9 to assess pancreatic cancer stage and 
resectability 
Pre-operative serum CA 19-9 is known to vary with disease stage. Kim et al. 
studied 114 PC patients who underwent either pancreatic resection (n=72) or 
palliative bypass (n=42). Mean pre-operative serum CA 19-9 was 40.05 
U/mL for patients with stage IA, 469.64 U/mL stage IIA, 747.79 U/mL stage 
IIB, 709 U/mL stage III and 3239 U/mL stage IV pancreatic cancer (85). A 
pre-operative CA 19-9 greater than 150 U/mL is known to correlate with an 
88% positive predictive value for surgical irrresectability (86) 
1.4.1.2.3 Serum CA 19-9 as a marker of prognosis and disease 
recurrence 
In a study of 129 surgically resected PC patients Berger et al. stratified 
patients into four groups based on pre-operative CA 19-9 (undetectable, 
normal < 37 U/mL, 38-200 U/mL and > 200 U/mL). Patients with 
undetectable or levels < 37 U/mL had an improved median survival (32 and 
35 months resepectively) compared to those with levels between 38-200 
U/mL (22 months) and greater than 200 U/mL (16 months) (87).  Smith et al. 
in 2008 similarly described significant survival variation with pre-operative CA 
19-9. Among a cohort of 109 patients with surgically resected tumours 
median survival was found to be 10.4 versus 22.1 months among patients 
with a pre-operative serum CA 19-9 of less than or greater than 150 U/mL, 
respectively (88).  
 
Post-operative CA 19-9 may also be similarly used to predict survival. Kondo 
et al. in a study including 109 surgically resected patients described that a 
CA 19-9 of <37 U/mL, < 200 U/mL and >500 U/mL measured 2-4 weeks 
post-operatively were associated with a 49%, 38% and 0% three-year 
survival rate respectively (89). 
1.4.1.2.4 Limitations of serum CA 19-9 
Serum CA 19-9 as a biomarker has several drawbacks. Firstly serum CA 19-
9 is only elevated in 80-85% of pancreatic cancer patients (84) and may 
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often fail to detect early stage malignancies (90). CA 19-9 is in addition 
related to the Lewis blood group antigen, and only patients belonging to the 
Le (α-β+) or (α+β-) blood groups will express CA 19-9. CA 19-9 as a 
biomarker is as such ineffective among the 5-10% of the population who are 
Lewis blood group antigen negative (82, 84). 
 
Serum CA 19-9 may also be elevated in non-malignant conditions such as 
pancreatitis, cirrhosis and cholangitis. Elevation may also occur in other 
gastrointestinal cancers such as gastric, oesophageal and 
cholangiocarcinoma (84, 91). 
 
One significant confounding factor is up-regulation of CA 19-9 among 
patients with hyperbilirubinemia due to either benign or malignant disease. 
This is clearly an important issue as painless obstructive jaundice is the most 
common presentation of pancreatic cancer (84, 92). In order to differentiate 
malignancy from benign disease it has been suggested that the upper limit 
(or cut-off level) for CA 19-9 be increased beyond 37 U/mL. Alternative 
strategies include to re-assess serum CA 19-9 post biliary drainage. Re-
assessing CA 19-9 however may lead to diagnostic delay. Marrelli et al. 
(among a cohort of 87 patients with pancreatico-biliary malignancy and 41 
benign controls) through increasing the upper cut-off limit of CA 19-9 to 90 
U/mL was able to describe an increase in CA 19-9 specificity for the 
diagnosis of malignant disease to 95%. Sensitivity however declined to 61%. 
In the same study serum CA 19-9 levels were elevated (>37 U/mL) among 
61% of benign cases and 86% malignant cases. Following biliary drainage 
CA 19-9 levels decreased in nearly all benign cases (41 of 42, 98%) but only 
in 19 of 38 (50%) patients with malignant biliary obstruction (93). 
1.4.2 Novel biomarkers for pancretic cancer  
Many novel biomarkers have been described through the use of various 
analytical techniques. I will describe a broad overview of such markers 
present within tissue and/or body fluid. A further detailed review of novel 
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biomarker discovery through NMR and metabonomic techniques are 
described within section 1.8. 
1.4.2.1 Novel biomarker markers in tissue 
1.4.2.1.1 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
The KRAS gene resides within the Ras family of oncogenes. Proteins 
produced from these genes are GTPases, which play an important role in 
cell division, cell differentiation and apoptosis. The KRAS mutation can be 
identified in up-to 90% of PC cases (94). PanIN-I, PanIN-II and PanIN-III 
lesions are also known to harbour this mutation in 36%, 44% and 87% of 
cases respectively (95). The diagnostic utility of KRAS is limited by its lack of 
sensitivity and specificity. Similar mutations have also been seen in chronic 
pancreatitis, gastric and colorectal cancer (96).  
1.4.2.1.2 Cyclin-dependent kinase inhibitor P16INK4A 
The loss of tumour suppressor p16INK4A function has been documented in up-
to 95% of PC cases (97, 98). P16INK4A mutations are however not specific for 
PC and have been observed in familial cases of malignant melanoma and 
breast carcinoma (97). Loss of p16INK4A however occurs at earlier stages of 
PC development along with PanIN (98, 99).  
1.4.2.1.3 Tumour suppressor p53  
The tumour suppressor p53 is the most frequently mutated gene in human 
cancers. The p53 mutation has been identified in up-to 70% of PC‟s (100). 
The p53 mutation appears late in PC development which limits it‟s 
usefulness for early disease detection (101).  
1.4.2.1.4 Smad4 gene 
The Smad4 protein mediates transforming growth factor beta (TGF-β) 
signalling to regulate cell growth and differentiation. SMAD4 is inactivated in 
55% of pancreatic cancers. Deletion of this protein correlates with a poor 
prognosis which is often due to metastatic disease (102). 
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1.4.2.2 Novel biomarkers in body fluid 
1.4.2.2.1 Macrophage inhibitory cytokine-1 (MIC-1) 
MIC-1 is a member of the transforming growth factor-β super-family (103). 
Macrophages are one of the sentinel cells of the innate immune system and 
provide a defense mechanism against cancer cells (104). MIC-1 presence in 
the tumor microenvironment limits the secretion of tumor necrosis factor-α 
(by activated macrophages) thereby reducing macrophage tumour killing 
activity (103). Koopmann et al. in 2006 identified serum MIC-1 as being 
significantly superior to CA19-9 in differentiating patient‟s with pancreatic 
cancer from healthy controls. 50 patients with resectable pancreatic cancer, 
50 patients with chronic pancreatitis and 50 age/sex matched healthy 
controls were included in the study. It was however not possible to 
distinguish pancreatic cancer from those patients suffering from chronic 
pancreatitis (105). 
1.4.2.2.2 Carcinoembryonic antigen-related cell adhesion molecule 1 
(CEACAM1)  
CEACAM1 is a cell-cell adhesion molecule found on leukocytes, epithelia, 
and endothelia. Multiple cellular activities have been attributed to CEACAM1 
including differentiation and arrangement of tissue structure, angiogenesis, 
apoptosis, tumor suppression and modulation of the innate and adaptive 
immune responses. CEACAM1 lacks sensitivity and specificity to be used as 
a diagnostic biomarker alone. Simeone et al. in 2007 described CEACAM1 
expression in the serum of 91% (74/81) of PC patients, 24% (15/61) of 
normal controls, and 66% (35/53) of patients with chronic pancreatitis (106). 
1.4.2.2.3 Micro ribonucleic acids (miRNAs) 
miRNAs were first discovered in 1993 and comprise of a class of highly 
conserved short (17-25 nucleotide) non-coding RNA products that regulate 
gene expression at the post-transcriptional level (107). miRNAs have shown 
promise for use as a biomarker for PC diagnosis, prognosis and 
chemosensitivity. Ma et al. (108) in a meta-analysis review (including 538 
cancerous and 206 non-cancerous controls) described varying tissue miRNA 
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expression including seven up-regulated (including miR-21, miR-155, and 
miR-221) and three down-regulated (miR-217, miR-148a, and miR-375) 
miRNAs. High levels of tissue miR-21, miR-23a, and miR-27a have more 
recently being associated with shorter survival times after surgical resection 
(109). 
Wang et al. in 2009 first described the detection of miRNAs within circulating 
blood plasma (110). Through profiling 28 pancreatic cancer and 19 control 
samples for miR-21, miR-210, miR-155 and miR-196, a sensitivity and 
specificity of 64% and 89% respectively was achieved for differentiating 
benign from neoplastic disease (110). Li et al. profiled sera from patients with 
pancreatic cancer (n=41), chronic pancreatitis (n=35), neuroendocrine 
tumours (n=18) and 19 healthy controls. Serum miR-1290 facilitated the 
detection of low stage pancreatic cancer from controls. Higher levels of miR-
1290 in addition correlated with poorer outcome among patients undergoing 
pancreaticoduodenectomy (111) .  
1.4.2.2.4 Glypican-1 
Melo et al. in 2015 through the use of mass spectrometry described 
identification of the cell surface proteoglycan glypican-1 (GPCI), specifically 
enriched on circulating cancer cell derived exosomes (crExos). Exosomes 
are lipid-bilayer-enclosed extracellular vesicles (containing proteins and 
nucleic acids) which are secreted by all cells and circulated within the 
bloodstream. Significantly higher levels of GPCI positive crExos from the 
serum of all 190 patients suffering from pancreatic adenocarcinoma when 
compared to 100 healthy donors (p<0.0001) were described (112). These 
findings are clearly very significant, however it must also be noted that levels 
were also significantly raised in 75% of a separate patient cohort of 32 
patients suffering from breast carcinoma within the same study. This clearly 
raises potential limitations with biomarker specificity.  
Through comparing patients with stage I-IV pancreatic cancer to healthy 
donors and to those with benign pancreatic disease (n=26), the receiver-
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operating characteristic curves revealed near perfect classification with an 
area under the curve of 1.0 exhibiting a sensitivity and specificity of 100%. 
Identical results were achieved through validation on an independent patient 
cohort composing of six patients suffering from chronic pancreatitis, 56 
PDAC and 20 healthy donors. In addition GPCI positive crExos levels were 
also described to correlate with disease burden. Levels were significantly 
raised among patients with distal metastatic disease over nodal disease over 
localised disease. Levels of GPCI positive crExos were also interestingly 
significantly raised among a cohort of patients suffering from pancreatic 
cancer precursor diseases (IPMNs). Patient numbers among this cohort 
were however small (n=5) (112). 
1.4.2.3 Novel biomarkers in stool 
Bone morphogenetic proteins (BMP) constitute a large subgroup within the 
transforming growth factor beta (TGF- β) super-family. BMP‟s are involved in 
a variety of developmental processes including tumour suppression (113). 
Kisiel et al. described elevated methylated BMP3 (mBMP3) in stool from 
PDA versus controls (non-neoplastic colonic epithelial controls) with a 
sensitivity and specificity of 51% and 90% respectively (113).  
1.5 Metabonomics & metabolomics 
Metabolomics is a newly emerging field of „omics‟ research concerned with 
the high-throughput identification, quantification and characterization of small 
molecule (<1500 Da) metabolites in the metabolome (114). Metabonomics is 
"the quantitative measurement of the dynamic multi-parametric metabolic 
response of living systems to pathophysiological stimuli or genetic 
modification" (115). 'Metabolomics' places emphasis on metabolic profiling at 
a cellular or organ level and is primarily concerned with normal endogenous 
metabolism, whereas 'Metabonomics' extends metabolic profiling to include 
information about perturbations of metabolism caused by environmental 
factors (including diet and toxins) and disease processes. These terms are 
often however used interchangeably. The metabolome can be defined as the 
complete complement of all small molecule (<1500 Da) metabolites found in 
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a specific cell, organ or organism. It is a close counterpart to the genome, the 
transcriptome and the proteome. Together these four „omes‟ constitute the 
building blocks of systems biology with the study of metabolites being the 
final downstream product of biological systems and hence closest to the 
phenotype. Thanks to the Human Genome Project most of the human 
genome, transcriptome and proteome are now know. Unfortunately the same 
cannot be said of the human metabolome. The Human Metabolome Project 
(HMP) was launched in 2004 as part of an effort to identify and quantify all 
detectable metabolites (>1 μM) in the human body (116). Over time 
metabolomics has evolved from a little-known branch of analytical chemistry 
to a mainstream enterprise.  
Metabolomics can be used in a variety of applications including biomarker 
identification, drug discovery or development and clinical toxicology (117). 
The two main technologies deployed for metabolome analysis are mass 
spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR). 
NMR has the advantage of being fast with minimal sample preparation and is 
cost-effective. Bio-fluid samples may be kept close to their native state and 
variability due to sample preparation (which is not labour intensive) is kept to 
a minimum. NMR samples are never in direct contact with the equipment and 
contamination between samples is minimal. NMR is highly reproducible and 
each sample may be re-run with only minor changes in results (118). MS is 
however widely used and is the standard technique in the pharmaceutical 
industry. MS is more sensitive than NMR but usually requires more extensive 
sample preparation, which unlike NMR can result in metabolite loss (119).   
Sensitivity is the largest weakness of NMR spectroscopy, which presents 
itself as a detection limit in the micromolar range rather than the nanomolar 
range as for MS. In addition a large water peak signal is always encountered 
during bio-fluid analysis, which may obscure metabolites. Low molecular 
weight metabolites can also be obscured by the broad envelope of high 
molecular weight resonances of proteins encountered during NMR 
acquisition. Both problems can be substantially addressed by application of 
appropriate pulse sequences (120). 
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1.6 NMR spectroscopy 
1.6.1 Classical and Quantum NMR Model 
The nuclear magnetic resonance (NMR) phenomenon was first reported in 
1946 (121). NMR exploits the behaviour of atomic nuclei in an externally 
applied magnetic field. Magnetic resonance occurs because of the quantum 
mechanical property of „spin‟, a source of angular momentum intrinsic to 
nuclei with an odd mass number. Examples of such nuclei include hydrogen-
1 (1H), carbon-13 (13C), fluorine-19 (19F) and phosphorous-31 (31P). The 
spinning nucleus like an electric current creates a tiny magnetic field. When 
placed in a strong magnetic field (B0) the magnetic nucleus tries to align like 
a compass needle in the Earth‟s magnetic field.  As the nucleus is spinning 
and has angular momentum the torque exerted by the external field results in 
a circular motion called precession (analogous to a spinning top in the 
Earth‟s gravitational field). The rate of precession is proportional to the 
external magnetic and nuclear magnetic field strength  (Figure 1.1) and is 
termed the Lamor frequency (v0) (122).    
 
Figure 1.1 Classical NMR model 
 
For “spin ½” nuclei there are two quantum states, which can be visualised as 
having the spin axis directed “up” or “down”. In the absence of an external 
magnetic field these two states possess equal energy and at thermal 
equilibrium exactly half of a population of nuclei will be in the “up” state and 
the remainder in the “down” state. In the presence of an external magnetic 
field the “up” state is aligned with the magnetic field and is lower in energy 
than the “down” state which opposes the external magnetic field (122). 
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Among a population of nuclei in thermal equilibrium, slightly more than half 
will reside in the lower “up” energy state.  
When a perpendicular radiofrequency (rf) pulse is applied the populations of 
the nuclear spins are disturbed and the bulk magnetisation is rotated from 
the z-axis (aligned with B0) towards the x-y plane (Figure 1.2).  
 
Figure 1.2 Effect of a 90° RF pulse on bulk magnetisation 
 
The spins subsequently return back to equilibrium, thus allowing energy 
levels to return back to the Boltzmann distribution, with a slight excess in the 
lower energy state (122, 123). This resonant frequency can be measured by 
applying a radio frequency signal to the sample and varying the frequency 
until absorbance of energy is detected (122). 
1.6.2 NMR pulsed Fourier transformation 
Early NMR spectrometers (continuous wave spectrometry) recorded a 
spectrum by slowly changing the radio frequency signal fed into a coil near 
the sample. When the frequency passed through a resonant frequency for a 
given nucleus a “peak” in the spectrum was recorded. Modern NMR 
spectrometers operate in “pulsed Fourier-transformation” mode. The 
collection of nuclei in a sample, are exposed to a strong radiofrequency 
pulse to stimulate precession in unison. Over time individual nuclei get out of 
synch and the signal dies down. This “echo” of the pulse is called the free 
induction decay (FID). Fourier transformation of the FID (Figure 1.3) converts 
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if from a signal as a function of time to a plot of intensity as a function of 
frequency (123).   
 
Figure 1.3 Fourier transformation of the FID 
 
1.6.3 NMR chemical shift 
The resonant frequency varies not only according to the type of nucleus but 
also on the position of that atom within a molecule (chemical environment). 
Bonding electrons create their own small magnetic field, which modifies the 
external magnetic field in the vicinity of the nucleus. This variation is called 
chemical shift and is measured in parts per million (ppm) (122, 123).  
1.6.4 NMR pulse sequences 
To visualise metabolites within bio-fluids with high water content the large 
dominant water signal must be suppressed (Figure 1.4). This is done through 
NMR pulse sequencing (which is also useful to suppress high molecular 
weight molecules such as protein). An understanding of longitudinal and 
transverse relaxation is fundamental to the understanding of NMR pulse 
sequencing and is described in section 1.6.5. 
  
19 
 
 
Figure 1.4 Suppression of the dominant water peak (a) through pulse 
sequencing (b) 
 
1.6.5 NMR longitudinal & transverse relaxation 
The dissipation of energy from the spins to the surrounding lattice and return 
of bulk magnetisation to the z-axis is known as longitudinal relaxation. The 
longitudinal relaxation time constant is defined as T1 (123).  If all spins 
experience an identical magnetic field, precession at the same frequency 
would occur. However, each spin will experience a different magnetic field 
due to the inhomogeneity of B0 along with local magnetic field variation 
existing within the sample (123).  Each sample can be thought of as being 
divided into several small regions (isochromats). Within each isochromat the 
magnetic field is uniform and the addition of these fields give rise to the total 
magnetisation. Unlike longitudinal relaxation, transverse relaxation is an 
entropic process as energy is transferred between spins rather than lost to 
the surrounding lattice (Figure 1.5). Given time the isochromats fan out as 
the bulk magnetisation reduces. Transverse relaxation is characterised by 
the time constant T2 (122, 123).  
(a) (b) 
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Figure 1.5 Fanning out of individual spins resulting in net zero magnetisation 
in the x-y plane (transverse relaxation) 
 
1.6.6 NMR spin-echo pulse sequence 
The different relaxation pathways for spins mean that T2 is always less than 
or equal to T1. The spin echo pulse sequence was devised to measure an 
accurate T2 value of a sample through attempting to reduce the effect of field 
inhomogeneity (122, 123). The initial 900x pulse pushes the magnetisation 
onto the y-axis where inhomogeneity of the static field causes isochromats to 
fan-out during the time period τ.  A second pulse rotates all the isochromats 
by 1800 to the –y-axis. This allows precessing isochromats to catch up with 
the average magnetisation vector, which is refocused (Figure 1.6). The 
second echo after 2τ is an exponential decay and is Fourier transformed to 
produce a spectrum.  
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Figure 1.6 Magnetisation during the spin-echo pulse sequence and 
refocusing of the magnetic vectors 
 
NMR spectra can be edited according to molecular size due to differences in 
T2 duration. Pulse sequences take advantage of this to suppress or enhance 
various molecules. To suppress large molecules such as protein, which have 
short T2 times a short τ delay is selected. The Carr-Purcell-Meiboom-Gill 
(CPMG) pulse sequence uses many repetitions of short τ delays and 180
0
x 
pulses. This technique removes signals from high molecular weight 
molecules (such as proteins) enabling those for small molecules to be 
resolved and quantified (Figure 1.7) (122, 123). 
 
Figure 1.7 CPMG spectrum of plasma 
т 
т 
α-glucose 
β-glucose 
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For urine data acquisition the 1D Nuclear Overhauser effect spectroscopy 
(NOESY) sequence is commonly used. This applies a pre-saturation pulse to 
the water signal to saturate the spins prior to acquisition and analysis (123).  
1.7 NMR Data analysis 
1.7.1 Chemometrics 
The science of metabonomics generates huge complex data tables that are 
hard to summarize with conventional statistics. Chemometrics utilises robust 
methods of modelling and analysis which take complicated 
chemical/biological data tables and produce interpretable and reliable 
statistical models (124). Principle component analysis (PCA) and partial least 
squares (PLS) analysis techniques are commonly used and will be discussed 
further. Prior to chemometric analysis NMR spectral data must be reduced, 
normalised and scaled (Figure 1.8). 
1.7.2 Data reduction 
Data reduction is commonly achieved through a process known as “binning”. 
Spectra are divided into smaller regions known as “bins” (125). Each of the 
“bins” are then integrated to achieve a numerical value that reflects the 
concentration of the species giving rise to the signal in that bin.   
1.7.3 Normalisation 
In metabonomic studies there will be samples where the total metabolite 
concentration will vary due to factors unrelated to the parameters being 
investigated. This is a feature of urine, which varies greatly in concentration. 
In the constant sum method the integral values of bins are summed to give a 
total value and then each bin integral is divided by this value. This allows 
signal intensities to be compared between samples (125). 
1.7.4 Scaling 
Metabolites of high concentration are not always the most informative. 
Scaling regulates the importance of each variable to avoid overlooking 
variation in lower concentration metabolites (126). Through subtracting the 
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mean from the entire sample set from each normalised variable the data may 
be mean centred (127). Division of centred data by the standard deviation of 
the whole sample set is known as Unit Variance and ensures all variables 
have the potential to influence the model (126, 127). To reduce the influence 
of spectra noise Pareto Scaling may be used whereby centred data is 
divided by the square root of the standard deviation of the whole sample 
(126, 127).  
1.7.5 Principle component analysis (PCA) 
PCA forms the basis for multivariate data analysis. PCA‟s main function is to 
reduce dimensions of a large unmanageable multivariate dataset (X) into a 
few manageable dimensions. The approximated data facilitates the 
identification of any clustering of samples within the overall dataset as well 
as outliers.  The PCA process starts with the transformation of a multivariate 
table of data into multidimensional co-ordinate space. For n observations 
(samples), a k dimensional space is constructed, where k is the number of 
variables. Each sample is represented as a single point co-ordinate 
according to each variable point within the k dimensional space. The first 
principle component, the linear combination of the original variables 
represents the largest variation in the swarm of points. The second 
component represents the second largest variation and so on (124).  The 
number of principle components in a model is determined by the difference in 
degree of fit and predictive ability of a model. The goodness of it is estimated 
by R2. When the number of components increases, R2 tends towards 1 as 
every value is predicted.  
Any two principle components can form a plane, onto which observation can 
be projected as a scores plot.  Observations that lie close to each other have 
similar multivariate hence metabonomic profiles. Strong outliers can be 
visualised by Hotelling‟s distribution which provides a tolerance region for the 
data (95% confidence interval) represented by an ellipse on the scores plot 
(124). Analogous to the scores plot, a loading plot may be generated which 
displays the weight or influence of individual variables in the model (124). 
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The loadings plot facilitates the identification of areas of the NMR spectrum 
accounting for maximum metabolic variation between samples (Figure 1.8).  
1.7.6 Partial least squares discriminant analysis (PLS-DA) 
Unlike PCA, partial least squares-discriminant analysis (PLS-DA) is a 
supervised method for multivariate analysis, which incorporates class 
membership to improve data separation. In addition to an X-matrix of 
observations (samples) and variables (bins), a Y-matrix consisting of class 
membership (case/control) is created. Orthogonal PLS (OPLS) may be used 
to enhance the interpretation of PLS by displaying all information into a 
single component for visual display (128). 
For validation purposes PLS-DA may be used to predict class membership of 
samples from the X-matrix data. One-third of samples can be randomly 
excluded followed by generation of a new model. This model is then used to 
predict class allocation of the excluded samples. Permutation testing is an 
alternative method. In a permutation test the class labels of case and control 
are permuted or randomly assigned to different classes. With incorrect class 
labelling a new classification model is calculated. Permutation testing 
demonstrates how models in which the Y-variables (class membership) are 
randomised compare to the original PLS-DA model. An R2 Y intercept value 
below 0.3-0.4 and a Q2 Y less than 0.05 indicates a valid model (128) . 
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Figure 1.8 Chemometric analysis through data reduction (“binning”) with 
subsequent scores and loadings plot 
    
1.8 Prior NMR metabonomic studies of pancreatic cancer 
1.8.1 Literature search 
A literature search (title and abstract) of Ovid Medline (R) (1948–2014), 
Embase (1974-2014), PubMed, Web of Science and Sci-Finder electronic 
databases was performed up to and including 11th October 2014. The search 
was conducted using the MeSH terms: nuclear magnetic resonance 
spectroscopy, metabolomic, metabonomic, metabolic profiling (AND) 
pancreatic cancer.  Studies comparing the metabolomic profile of human 
biological samples of pancreatic cancer with a control arm by NMR 
spectroscopy were included. Studies analysing the proteome, in-vivo imaging 
studies, animal studies, studies without a control arm and studies that 
reported the same patient population were excluded. Extracted data included 
primary author, date of publication, sample modality and number, the 
analytical platform used and statistically different metabolites between 
cancer and control arms of the study. The primary outcome measure was the 
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identification of metabolites found to have statistically different abundances 
between cancer and control samples.  
1.8.2 Study identification and review 
Eight studies met the inclusion criteria for systematic review. The biological 
samples used for analysis among the eight pancreatic cancer studies 
included serum (n=3), plasma (n=1), urine (n=2), bile (n=1) and pancreatic 
fluid (n=1). 1H NMR was the metabolic platform used in all studies (Table 
1-1). The metabolites identified to be either up or down regulated 
respectively are highlighted in Table 1-2. 
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Table 1-1 Prior metabonomic studies of pancreatic cancer utilising 1H NMR 
 
Author & 
Year 
Sample Pathology Cancer 
(n) 
Control Control 
(n) 
Up-regulated Down regulated Other findings/comments  Ref. 
Bezabeh T, 
2009 
Bile PC 4 BB 10  D-glucuronic acid    (129) 
CP 3   
Zhang L, 2012 Plasma PC 19 HV 20 PC vs controls: N-acetyl 
glycoprotein, VLDL, lipid 
glyceryl, dimethylamine, 
acetone 
PC vs. controls: 3-
hydroxybutyrate, citrate, 
lactate, LDL, HDL, valine, 
lysine, leucine, 
isoleucine, histidine, glutamine, 
glutamate and alanine 
 (130) 
CP 20 CP vs. controls:glucose, 
lactate, creatine, formate, lipid 
glyceryls, tyrosine, 
phenylalanine, lysine, 
histidine, glutamine, 
glutamate, alanine 
CP vs. controls:LDL, VLDL, 3-
hydroxybutyrate and acetone 
PC vs. CP: NAG, VLDL, 
dimethylamine, acetone 
PC vs. CP: 3-hydroxybutyrate, 
creatine, lactate, citrate, 
LDL, HDL, lipid glyceryl, 
formate, valine, tyrosine, 
phenylalanine, lysine, 
isoleucine, histidine, glutamine, 
glutamate, and alanine 
Bathe OF, 
2010 
Serum PC 43 BB 41 Glutamate, glucose Creatine, glutamine  (131) 
OuYang D, 
2011 
Serum  PC 17 HV 23 Isoleucine, triglyceride, 
leucine, creatinine 
3-hydroxybutyrate, 3-
hydroxyisovalerate, lactate, 
trimethylamine-N-oxide 
 (132) 
Tesiram YA, 
2012 
Serum  PC 14 HV 12 Choline, taurine, glucose, 
triglycerides 
  (133) 
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Author & 
Year 
Sample Pathology Cancer 
(n) 
Control Control 
(n) 
Up-regulated Down regulated Other findings/comments  Ref. 
Davis VW, 
2012 
Urine PDA 32 HV 32 Acetone, hypoxanthine, O-
acetylcarnitine, 
dimethylamine, choline, 1-
methylnicotinamide, threonine, 
fucose, cis-aconitate, 4-
pyridoxate, glucose, 
trimethylamine-N-oxide, 
aminobutyrate, tryptophan, 
xylose, trans-aconitate, 4-
hydroxyisobutyrate, taurine 
Trigonelline, methanol 11 metabolites no longer significantly 
raised in post-op period 
(134) 
Napoli C, 2012 Urine PDA 33 HV 54 Acetoacetate, acetylated 
compounds, glucose, leucine, 
2-phenylacetamide 
Citrate, creatinine, glycine, 
hippurate, 3-hydroxyisovalerate 
 (135) 
Wang J, 2011 Pancreatic 
fluid 
PC 10 HV 5   Triplet peak of the methyl ethoxy group 
(CH3CH2O-) at chemical shift of 1.19 
ppm in alcoholic chronic pancreatitis 
(136) 
CP 5 
Cirrhosis 15 
 
 
  
29 
 
Table 1-2 Prior metabonomic studies of pancreatic cancer and metabolite 
identification through 1H NMR analysis 
 
Metabolite 
Study (ref) 
Zhang L 
(130) 
Bathe OF 
(131) 
OuYang D 
(132) 
Tesiram YA 
(133) 
Davis VW 
(134) 
Napoli C 
(135) 
Glucose 
 
↑ 
 
↑ ↑ ↑ 
Citric Acid/Citrate ↓ 
     
Lactate ↓ 
 
↓ 
   
Acetone ↑ 
   
↑ 
 
Isoleucine ↓ 
 
↑ 
   
Leucine ↓ 
 
↑ 
  
↑ 
Lysine ↓ 
     
Threonine 
    
↑ 
 
Tryptophan 
    
↑ 
 
Valine ↓ 
     
Alanine ↓ 
     
Glutamine ↓ ↓ 
    
Glutamate ↓ ↑ 
    
Taurine 
   
↑ ↑ 
 
VLDL ↑ 
     
LDL ↓ 
     
HDL ↓ 
     
Triglyceride 
  
↑ ↑ 
  
Choline 
   
↑ ↑ 
 
N-acetyl glycoprotein ↑ 
     
Dimethylamine ↑ 
   
↑ 
 
1-methylnicotinamide 
    
↑ 
 
2-phenylacetamide 
     
↑ 
Trimethylamine-N-oxide 
  
↓ 
 
↑ 
 
Aminobutyrate 
    
↑ 
 
3-hydroxybutyrate ↓ 
 
↓ 
   
4-hydroxyisobutyrate 
    
↑ 
 
3-hydroxyisovalerate 
  
↓ 
   
Acetoacetate 
     
↑ 
O-acetylcarnitine 
    
↑ 
 
Cis-aconitate 
    
↑ 
 
4-pyridoxate 
    
↑ 
 
Creatine 
 
↓ 
    
Creatinine 
  
↑ 
   
Hypoxanthine 
    
↑ 
 
Xylose 
    
↑ 
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Metabolite 
Study (ref) 
Zhang L 
(130) 
Bathe OF 
(131) 
OuYang D 
(132) 
Tesiram YA 
(133) 
Davis VW 
(134) 
Napoli C 
(135) 
Trans-aconitate 
    
↑ 
 
Ttigonelline 
    
↓ 
 
Methanol 
    
↓ 
 
 
As displayed in Table 1-1 and Table 1-2 it is clear that metabolite variation 
exists between pancreatic cancer and control patients. The most commonly 
identified metabolites (in two or more studies) are glucose, lactate, acetone, 
isoleucine, leucine, glutamine, glutamate, taurine, triglyceride, choline, 
dimethylamine, trimethylamine-N-oxide and 3-hydroxybutyrate (Table 1-2). 
Concordant findings are described for glucose (up-regulated), lactate (down 
regulated), acetone (up-regulated), glutamine (down-regulated), taurine (up-
regulated), triglyceride (up-regulated), choline (up-regulated), dimethylamine 
(up-regulated) and 3-hydroxybutyrate (down-regulated) in cancer states. 
Contradictory findings are however apparent for isoleucine, leucine, 
glutamate and trimethlamine-N-oxide (Table 1-2). Contradictory results may 
be due to differences in sample collection, poor documentation of histology 
or control patient recruitment, the biological medium investigated or specific 
1H NMR technique (Table 1-3).  
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Table 1-3 Prior metabonomic study design and patient enrolment 
 
 
Bezabeth T (129) Zhang L (130) Bathe OF (131) OuYang D (132) 
Tesiram YA 
(133) 
Davis VW (134) Napoli C 127) 
Wang J 
(136) 
Benign/controls 
Cohort 
CBD calculi (6), CP (3), 
post-liver transplant (1) 
Healthy controls (20), CP (20) Benign PB (43)  
Healthy controls 
(23) 
Healthy 
controls (12) Healthy controls (32) 
age/sex matched 
Healthy controls 
(54) age matched 
CP (5) 
Exclusions - Any PMH Acute or sepsis 
No PMH or recent 
illness 
- 
Infection, renal failure, 
breast feeding, 
pregnancy 
No PMH 
 
Age 
Y Y Y Y Y Y Y Y 
Sex 
Y Y Y Y Y Y Male only Y 
Ethnicity 
- - - - - - - - 
BMI 
- Y - - - - Yes - 
PMH 
- Y Y Y Y Y Y - 
Drug History 
- - - Y - Y Y - 
Bilirubin 
Y Y Y Y - Y - - 
Cancer cohort 
Cell-line 
PC (4), papillary cancer 
(1), cholangiocarcinoma 
(1), myeloma (1) 
PC (19) PDA (56) PC (17) PDA (14) PDA (32) PDA (33) PC (10) 
Exclusion 
- - Acute inflammation or sepsis 
No PMH or recent 
illness 
- 
Infection, renal failure, 
pregnancy   
Grade 
- - - - - Y Y - 
Staging 
- - - - Y Y Y - 
Age 
Y Y Y Yes Y Y Y Yes 
Sex 
Y Y Y Yes Y Y Male only Yes 
  
32 
 
Ethnicity 
- - - - - - - - 
BMI 
- Y - - - - - - 
PMH 
- - Y Y - - Y - 
Drug History 
- - - Y - - Y - 
Bilirubin 
Y - Y - - - - - 
Resectability 
- - Y - - Yes - - 
Survival 
- - - - - - - - 
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1.9 Plan of investigation 
The main aim of this work is to determine any variation in the metabolic 
profile among patients with pancreatic carcinoma for potential diagnostic 
purposes. Through the use of 1H NMR spectroscopy both plasma and urine 
will be profiled. Clear attention will be made to document the histological cell 
type, staging and grading among pancreatic cancer patients along with 
known confounders such as sex and race. In contrast to previous studies the 
metabolic profiles of patients with pre-malignant conditions will be compared 
against those with both confirmed malignancy and benign disease.   
1.9.1 Hypothesis testing 
A hypothesis is a statement about a population to be tested. The hypothesis 
of “no difference” within a population is called the null hypothesis(137). 
Within the context of this work a null hypothesis would be that there is no 
statistical difference between the mean integral peak in the NMR spectrum 
among patients with, versus those without PC. Acceptance or rejection of the 
null hypothesis is determined by a p-value, which is related to the means of 
two groups. The p-value is the probability of obtaining a test statistic test 
result at least as extreme as the one that was actually observed, assuming 
that the null hypothesis is true. A p-value of ≤0.05 is taken as statistically 
significant (137).   
1.9.2 Biomarker model generation 
We describe wherever possible any generated metabolic model for 
pancreatic cancer in terms of sensitivity, specificity, positive and negative 
predictive values through internal model validity testing.  
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2 Experimental methods 
2.1 Ethical approval for study 
This study was approved by the National Research Ethics Service (REC 
GS11/10064). The study conformed to the ethical guidelines outlined in the 
1975 Declaration of Helsinki. Written informed consent was obtained for all 
patients.  
2.2 Patient selection 
2.2.1 Patient enrolment 
Fifty-five patients undergoing pancreatic resection for presumed malignancy 
were enrolled into the study. Only patients undergoing surgery were 
approached for inclusion due to availability of post-operative histology. To act 
as a control arm for the study patients undergoing surgery for benign 
pancreaticobiliary disease were enrolled. Exclusion criteria included 
paediatric pancreatic resections, patients with a history of known diabetes 
mellitus and those with evidence of recent (within one week) or active 
infection at the time of surgery. A total of 34 patients with known benign 
disease and 55 with presumed malignant disease were recruited. Among 
those with presumed malignant disease only 10 patients were cytology or 
biopsy proven pre-operatively with a further two displaying highly suspicious 
cytology for malignancy (cellular atypia and pleomorphic nuclei). Eleven 
patients who underwent surgery for presumed malignant disease were 
shown on post-operative histology review to have either benign or pre-
malignant disease. As such two initial groups of confirmed malignancy (n=44) 
and confirmed benign/pre-malignant (n=45) were formed. Each plasma 
sample was coded by the prefix “C” for confirmed cancer versus “B” for 
confirmed benign followed by “R” for plasma or “U” for urine followed by the 
subsequent sample number.  
2.2.2 Confirmed malignancy patient cohort 
A total of 44 patients with confirmed malignancy were recruited into the study. 
27/44 (61%) of patients were male with an overall median age of 66 (40-81) 
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years. Among the cancer resection cohort twenty-eight patients underwent 
surgical resection (19 pylorus-preserving pancreaticoduodenectomy (PPPD), 
6 distal pancreatectomy, one enucleation for early neuroendocrine tumour, 
one total pancreatectomy and one wide excision of gallbladder fossa and 
common bile duct excision for gallbladder carcinoma). Sixteen patients at 
time of laparotomy were found to have either locally advanced (n=11) or 
metastatic (n=5) disease. Of these thirteen underwent palliative single (n=3) 
or double bypass (n=8).  Data regarding patient demographics, clinical 
presentation, pre-operative serum bilirubin, operative intervention, histology, 
chemotherapy and recurrence were collected (Table 2-1). Past-medical and 
prescription history is displayed in Table 2-2. 
2.2.3 Confirmed benign patient cohort 
A total of 45 patients with confirmed benign disease were recruited. 19/45 
(42%) of patients were male with an overall median age of 53 (20-85) years. 
Thirty-one underwent cholecystectomy for gallstone disease. Among 
pancreatic resections performed for presumed pre-malignant or malignant 
change four had histology confirming dysplastic change whereas six had 
benign histology. Two patients underwent pancreaticojejunostomy for chronic 
pancreatitis, a further patient duodenal resection for low-grade gastro-
intestinal stromal tumour and one patient open local excision of a 
retroperitoneal paraganglionoma. Patient demographics are displayed in 
Table 2-3 and patient past medical and prescription history in Table 2-4. 
2.2.4 Cancer versus benign cohort age and sex variation 
Patients among the confirmed cancer cohort were older than those with 
benign disease. A greater proportion of the benign cohort were female 
although statistical significance was not reached (Table 2-5) 
2.2.5 CA 19-9 
Among 55 patients undergoing surgery for potential malignancy, pre-
operative serum CA 19-9 levels were available at the time of patient 
recruitment in 70.9% (n=39) patients. Among 55 patients undergoing surgery 
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44 (80%) were for histologically proven neoplastic disease and 11 (20%) for 
benign disease. Among 44 patients with neoplastic disease pre-operative 
serum CA 19-9 levels were available in 28 patients. Using an upper limit CA 
19-9 of 37 u/mL, levels were raised pre-operatively in 20 (71.4%) of patients. 
Pre-operative CA 19-9 levels were within the normal range among all eleven 
patients who underwent surgery for histologically benign disease. Among this 
small cohort sensitivity and specificity of 71.4% and 100% respectively with 
positive and negative predictive values of 71.4% and 57.9% respectively 
were achieved for CA 19-9 as a diagnostic pre-operative biomarker.  
Among the 28 patients with available pre-operative CA 19-9, 17 (60.7%) 
underwent pancreatic resection with 11 (39.3%) having irresectable disease. 
CA 19-9 was raised over and above 150 u/mL in 6 (35.3%) patients who 
underwent resection and was less than 150 u/mL among 3 (27.3%) patients 
with irresectable disease. Using CA 19-9 > 150 u/mL as a marker of 
irresectability failed to reach statistical significance among our patient cohort 
(p=0.1201). 
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Table 2-1 Cancer resection patient cohort 
 
Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
ERCP 
stent 
(y/n) 
Pre-op 
bilirubin 
(micromol/L) 
Ca 19-
9 
(u/ml) 
Operation Diagnosis Differentiation Histology/Cytology 
Adj 
Chemo 
(y/n) 
Recurrence 
DFS 
(mths) 
OS 
(mths) 
CR CU 
1 1 F 73 Caucasian y 10 156 PPPD PDA Mod-poor T3N1V1R1 y 12 12 15 
2 2 F 48 Caucasian y 40 ─ PPPD PDA Mod T3N1V1R1 y 9 9 14 
3 3 F 63 Caucasian y 55 196 PPPD PDA Mod-poor T3N1V1R1 y 13 13 17 
Spoiled 4 F 80 Caucasian y 60 240 Palliative PDA Mod Adenocarcinoma n Locally advanced 0 15 
5 5 M 65 Caucasian y 53 13711 Palliative PDA Mod Adenocarcinoma y Metastatic disease at surgery 0 6 
6 6 F 71 Caucasian y 129 100 PPPD Ampullary carcinoma Poor T4N1V1R1 y 9 9 18 
7 7 M 58 Caucasian y 14 436 PPPD PDA Mod-poor T3N1V1R1 y ─ 26 ─ 
8 8 M 73 Caucasian y 116 1069 Palliative PDA Mod Adenocarcinoma y Locally advanced 0 ─ 
9 9 M 65 Caucasian y 48 432 Palliative PDA Mod Adenocarcinoma n Metastatic disease at surgery 0 6 
10 10 F 78 Caucasian y 19 ─ PPPD Adenocarcinoma from side branch IPMN Mod-poor T3N1V1R1 n 16 16 23 
11 11 F 66 Caucasian y 86 2774 Palliative PDA Mod Adenocarcinoma 0 Metastatic disease at surgery 0 2 
12 12 M 65 Caucasian y 53 437 Palliative PDA Mod-poor Adenocarcinoma y Locally advanced 0 15 
13 13 M 76 Pakistani y 10 ─ PPPD Ampullary carcinoma Well T4N1V1R1 0 12 12 14 
14 14 M 67 Caucasian y 9 1271 Palliative PDA Well 
Adenocarcinoma 
n Locally advanced 0 18 
15 15 M 63 Caucasian n 132 ─ Palliative Duodenal Carcinoma Poor 
Adenocarcinoma 
y Locally advanced 0 10 
16 16 F 69 Caucasian y 9 164 PPPD PDA Mod T3N1V1R1 n ─ 24 ─ 
17 17 M 74 Caucasian y 28 ─ PPPD PDA Mod T3N1V1R1 y ─ 9 ─ 
18 18 F 70 Caucasian y 9 ─ Palliative Distal cholangiocarcinoma Mod Adenocarcinoma n Locally advanced 0 ─ 
19 19 M 68 Caucasian n 20 5 LDP + splen Neuroendocrine Well T2N0V0R0 n ─ 9 ─ 
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Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
ERCP 
stent 
(y/n) 
Pre-op 
bilirubin 
(micromol/L) 
Ca 19-
9 
(u/ml) 
Operation Diagnosis Differentiation Histology/Cytology 
Adj 
Chemo 
(y/n) 
Recurrence 
DFS 
(mths) 
OS 
(mths) 
CR CU 
20 20 M 80 Caucasian n 7 17 Palliative Duodenal Carcinoma Mod Adenocarcinoma y Locally advanced 0 8 
21 21 M 62 Caucasian n 10 171 PPPD Acinar cell carcinoma Mod T3NOR1 y ─ 9 ─ 
22 22 M 59 Caucasian y 7 62 Palliative PDA Poor Adenocarcinoma y Metastatic disease at surgery 0 ─ 
23 23 M 65 Caucasian y 41 ─ Palliative PDA Poor Adenocarcinoma y Locally advanced 0 ─ 
24 24 F 71 Caucasian n 5 ─ ODP + splen Adenosquamous carcinoma Poor T3N1V1R1 n ─ 8 ─ 
25 25 F 61 Caucasian n 9 ─ Enucleation Neuroendocrine Well T1NxV0R1 n ─ 8 ─ 
26 26 F 81 Caucasian y 13 26 
Wide excision 
GB, CBD 
resection 
Gallbladder carcinoma Poor T2N1R1 n ─ 8 ─ 
27 27 M 66 Caucasian y 9 91 PPPD PDA Mod T3N1V1R1 y ─ 7 ─ 
28 28 F 40 Caucasian y 37 ─ Palliative Neuroendocrine Poor Neuroendocrine y Metastatic disease at surgery 0 2 
29 29 M 72 Caucasian n  9 53 Palliative PDA Mod Adeno CA y Locally advanced 0 ─ 
30 30 M 45 Caucasian n 15 ─ LDP Neuroendocrine Well T2N0MxR0 n ─ 7 ─ 
31 31 M 62 Caucasian y 12 90 PPPD PDA Mod T3N1V1R1 y ─ 6 ─ 
32 32 M 66 Caucasian n 11 25 ODP Pancreatic adenosquamous Mod T3N1V1R1 y ─ 6 ─ 
33 33 F 66 Caucasian y 40 436 Palliative PDA Poor Adenocarcinoma y Locally advanced 0 ─ 
34 34 M 45 Caucasian n 12 11 PPPD PDA Mod T3N1V1R1 n ─ 5 ─ 
35 35 M 68 Caucasian y 29 ─ Palliative PDA Mod Adenocarcinoma y Locally advanced 0 5 
36 36 M 75 Caucasian y 14 ─ PPPD PDA Poor T3N1V1R1 n 4 5 ─ 
37 37 M 79 Caucasian n 9 5 PPPD Colloid carcinoma arising within main duct IPMN  Mod T3N1V0R1 y ─ 5 ─ 
38 38 F 59 Caucasian y 28 19 TP + splen Colloid carcinoma arising within main duct IPMN  Mod T3N1V0R0 y ─ 5 ─ 
39 39 M 73 Caucasian PTC 10 213 PPPD Ampullary carcinoma Mod T4N1V1R0 y ─ 5 ─ 
40 40 M 76 Caucasian y 6 66 PPPD Ampullary carcinoma Mod T3N1R1 y ─ 4 ─ 
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Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
ERCP 
stent 
(y/n) 
Pre-op 
bilirubin 
(micromol/L) 
Ca 19-
9 
(u/ml) 
Operation Diagnosis Differentiation Histology/Cytology 
Adj 
Chemo 
(y/n) 
Recurrence 
DFS 
(mths) 
OS 
(mths) 
CR CU 
41 41 M 50 Caucasian y 12 ─ PPPD Distal cholangiocarcinoma Mod T3N1V1R1 n ─ 4 ─ 
42 42 F 64 Caucasian n 7 ─ 
ODP + splen + 
gastrectomy + 
transverse 
colectomy 
PDA Poor T3N1V1R1 n ─ 4 ─ 
43 43 F 54 Caucasian y 24 ─ PPPD PDA Poor T3N0V1R1 y ─ 4 ─ 
44 44 M 69 Caucasian n 16 28 ODP + splen PDA Mod T3N1V1R1 y ─ 3 ─ 
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Table 2-2 Cancer resection patient cohort past medical and pharmaceutical history 
 
Sample Code 
Presenting features 
Pancreatic tumour 
site 
Tumour size (mm) Past medical history Drug history 
CR CU 
1 1 Jaundice Uncinate 20.0 HTN, IHD, Hypothyroid 
Lansoprazole, aspirin, biosprolol, nicorandil, 
levothyroxine, losaran 
2 2 Jaundice Head 24.0 Retinoblastoma, 1b malignant melanoma Lansoprazole 
3 3 Jaundice Head 25.0 T2N1 Breast Cancer ─ 
Spoiled 4 Abdo pain + jaundice Head 30.0 ─ ─ 
5 5 Jaundice Head 28.0 ─ Glicalzide, ramipril, amlodipine, omeprazole 
6 6 Abdo pain  Head 28.0 T1N0 Breast Cancer 
Anastrazole, aspirin, budesonide, carbocistine, 
omeprazole, simvastatin 
7 7 Jaundice Head/neck 40.0 Gastro-oesophageal reflux, HTN Loratidine, atenolol 
8 8 Jaundice Head 34.0 ─ ─ 
9 9 Jaundice Head 40.0 Epilepsy Tegretol 
10 10 Jaundice Head 50.0 HTN Atenolol, valsartan, methyldopa 
11 11 Jaundice Head 32.0 HTN Lisinopril 
12 12 Jaundice Head 30.0 ─ ─ 
13 13 Jaundice Ampulla 15.0 HTN, IHD Aspirin, biosoprolol, levothyroxine, ramipril 
  
41 
 
Sample Code 
Presenting features 
Pancreatic tumour 
site 
Tumour size (mm) Past medical history Drug history 
CR CU 
14 14 Jaundice Neck 35.0 ─ ─ 
15 15 Gastric outflow obst Head Undefined ─ ─ 
16 16 Jaundice Ampulla 17.0 Polymyalgia rheumatica Prednisolone, pantoprazole 
17 17 Jaundice Uncinate 35.0 HTN Bendroflumethiazide, enalapril 
18 18 Jaundice Uncinate 15.0 
 
─ 
19 19 Abdo pain Body/tail 28.0 HTN, IHD 
Salbutamol, ramipril, bisoprolol, simvastatin, aspirin, 
furosemide, naproxin 
20 20 GI bleed Duodenal 30.0 T4N0M1 mid-sigmoid & asc colon cancer (resected) 
Aspirin, ferrous sulphate, quinine, gabapentin, 
pantoprazole, lope amide, folic acid 
21 21 Abdo pain Head 33.0 ─ ─ 
22 22 Abdo pain Ampulla 15.0 ─ ─ 
23 23 Jaundice Head 20.0 Diffuse large B cell lymphoma (prior R CHOP) Gliclazide, metformin 
24 24 Abdo pain Tail 30.0 ─ ─ 
25 25 Hypoglycaemia Head 15.0 COPD Diazoxide, seretide, tiotropium 
26 26 Jaundice Gallbladder 10.0 HTN Bendroflumethiazide, doxazosin, simvastatin 
27 27 Jaundice Head 32.0 HTN Ranitidine, aspirin 
28 28 Jaundice Ampulla 16.0 ─ ─ 
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Sample Code 
Presenting features 
Pancreatic tumour 
site 
Tumour size (mm) Past medical history Drug history 
CR CU 
29 29 Abdo pain Uncinate 48.0 HTN, IHD 
Amlodipine, citirizine, citalopram , pravastatin, 
salbutamol, GTN 
30 30 Incidental  Tail 35.0 Multiple endocrine neoplasia 1 - parathyroidectomy ─ 
31 31 Jaundice Head 25.0 ─ ─ 
32 32 Incidental Tail 48.0 Chronic lymphocytic leukaemia, IHD Bisoprolol, simvastatin 
33 33 Jaundice Head 20.0 ─ ─ 
34 34 Incidental Head 13.0 Ulcerative colitis ─ 
35 35 Chang bowel habit Head 32.0 ─ ─ 
36 36 Jaundice Head 37.0 ─ ─ 
37 37 Panc Insuff Head 18.0 Asthma ─ 
38 38 Abdo pain and Jaundice Head 25.0 COPD, Peripheral vascular disease, hypothyroid Thyroxine 
39 39 Jaundice Ampulla 25.0 
Prostate cancer, monoclonal gammopathy of unknown 
significance 
Atorvastatin, bendroflumethiazide, amlodipine, 
omeprazole 
40 40 Gastric outflow obst Ampulla 25.0 Benign prostatic hypertrophy Tamsulosin, finasteride 
41 41 Jaundice Ampulla 10.0 ─ ─ 
42 42 Abdomial pain Body/tail 79.0 Squamous cell carcinoma of skin ─ 
43 43 Jaundice Uncinate 30.0 Hypothyroid, asthma Levothyroxine, seretide, salbutamol 
44 44 Incidental Neck 35.0 ─ ─ 
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Table 2-3 Benign patient cohort 
 
Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
Pre-op Bilirubin 
(micromol/L) 
Operation Pathology 
Benign (0)/Pre-malignant 
histology (1) 
BR BU 
1 1 F 23 Caucasian 13 Lap chole Gallstones/acute cholecystitis 0 
2 2 F 50 Pakistani 38 PPPD T2 AIP 0 
3 No urine F 25 Caucasian 8 Lap chole Gallstones/chronic cholecystitis 0 
4 No urine F 54 Caucasian 6 Lap chole Gallstones/chronic cholecystitis 0 
No plasma 5 F 62 Caucasian 5 LDP + splen Mixed type IPMN focal high grade dysplasia 1 
6 6 F 59 Caucasian 8 PPPD Side branch IPMN low and moderate dysplasia 1 
No plasma 7 M 48 Caucasian 3 Pancreaticojejunostomy Chronic pancreatitis 0 
8 8 F 72 Caucasian 9 LDP + splen Mixed type IPMN intermediate dysplasia 1 
9 9 F 62 Caucasian 9 Lap chole Gallstones/chronic cholecystitis 0 
10 10 F 37 Caucasian 11 Lap chole Gallstones/chronic cholecystitis 0 
11 11 F 55 Caucasian 3 Lap chole Gallstones/chronic cholecystitis 0 
12 12 M 78 Caucasian 6 Open chole Gallstones/chronic cholecystitis 0 
No plasma 13 F 34 Caucasian 14 Lap chole Gallstones/chronic cholecystitis 0 
14 14 M 84 Caucasian 11 Lap chole Gallstones/chronic cholecystitis 0 
15 15 F 34 Caucasian 8 Open chole Gallstones/chronic cholecystitis 0 
16 16 M 79 Caucasian 21 Open chole Gallstones/chronic cholecystitis 0 
17 17 M 71 Caucasian 23 Lap chole Gallstones/chronic cholecystitis 0 
18 18 F 46 Caucasian 5 Lap chole Gallstones/chronic cholecystitis 0 
19 19 M 47 Caucasian 7 Lap chole Gallstones/chronic cholecystitis 0 
20 20 M 72 Caucasian 9 PPPD Side branch IPMN no malignancy 0 
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Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
Pre-op Bilirubin 
(micromol/L) 
Operation Pathology 
Benign (0)/Pre-malignant 
histology (1) 
BR BU 
21 21 F 24 Caucasian 7 Lap chole Gallstones/chronic cholecystitis 0 
22 22 F 76 Caucasian 7 ODP + splen Serous cystadenoma 0 
23 23 M 65 Caucasian 7 Open chole Gallstones/chronic cholecystitis 0 
24 24 F 29 Polish 4 Lap chole Gallstones/chronic cholecystitis 0 
25 25 M 42 Caucasian 7 Lap chole Gallstones/chronic cholecystitis 0 
26 26 F 21 Caucasian 13 Lap chole Gallstones/chronic cholecystitis 0 
27 27 M 46 Caucasian 7 LDP + splen Benign cyst 0 
28 28 F 62 Caucasian 4 Duodenal resection Low grade GIST 1 
29 29 F 58 Caucasian 10 Open chole + splenectomy Gallstones/chronic cholecystitis 0 
30 30 F 42 Pakistani 9 Lap chole Gallstones/chronic cholecystitis 0 
31 31 M 57 Polish 10 Lap chole Gallstones/chronic cholecystitis 0 
32 32 M 62 Pakistani 11 Lap chole Gallstones/chronic cholecystitis 0 
33 33 M 42 Caucasian 15 PPPD IPMN  intermediate grade dysplasia 1 
34 34 M 20 Caucasian 15 Lap chole Gallstones/chronic cholecystitis 0 
35 35 F 67 Caucasian 9 Local excision Paraganglioma 0 
36 36 M 52 Caucasian 4 Hepaticojejunostomy Chronic pancreatitis 0 
37 37 M 42 Caucasian 14 Lap chole Gallstones/chronic cholecystitis 0 
38 38 F 68 Caucasian 7 ODP + splen Serous microcystic adenoma 0 
39 39 F 75 Caucasian 8 Lap chole Gallstones/chronic cholecystitis 0 
40 No urine F 85 Caucasian 5 Lap chole Gallstones/chronic cholecystitis 0 
41 41 M 38 Caucasian 20 Lap chole Gallstones/chronic cholecystitis 0 
42 42 M 44 Caucasian 6 Lap chole Gallstones/chronic cholecystitis 0 
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Sample Code 
Sex 
Age 
(yrs) 
Ethnicity 
Pre-op Bilirubin 
(micromol/L) 
Operation Pathology 
Benign (0)/Pre-malignant 
histology (1) 
BR BU 
43 43 F 22 Caucasian 13 Lap chole Gallstones/chronic cholecystitis 0 
44 44 M 53 Caucasian 5 ODP + splen Chronic pancreatitis 0 
45 45 F 70 Caucasian 7 Lap chole Gallstones/chronic cholecystitis 0 
 
Table 2-4 Benign patient cohort past-medical and drug history 
 
Sample Code 
Operative Indication Past medical history Drug history 
BR BU 
1 1 Biliary colic ─ ─ 
2 2 Presumed malignancy ─ ─ 
3 No urine Biliary colic ─ ─ 
4 No urine Biliary colic ─ ─ 
No plasma 5 Main duct IPMN pancreatitis HTN Co-tenidone 
6 6 Presumed malignancy ─ ─ 
No plasma 7 Chronic pancreatitis dilated pancreatic duct Chronic pancreatitis ─ 
8 8 Presumed malignancy 2013 Anterior resection (Dukes B rectal cancer) ─ 
9 9 Biliary colic Hiatus hernia Solifenacin, lansoprazole 
10 10 Biliary colic ─ ─ 
11 11 Biliary colic ─ ─ 
12 12 Prior cholecystitis IgA lambda myeloma 2009 ─ 
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Sample Code 
Operative Indication Past medical history Drug history 
BR BU 
No plasma 13 Acute pancreatitis ─ ─ 
14 14 Acute pancreatitis ─ ─ 
15 15 Biliary colic 
Breast ductal carcinoma in-situ  (Excision and 
radiotherapy) 2013 
─ 
16 16 Prior cholecystitis Right thoracoplasty 1963 (TB) ─ 
17 17 Prior cholecystitis CABG, atrial fibrillation 
Warfarin, biosprolol, diltiazem, ramipril, simvastatin, 
salbutamol, seretide 
18 18 Prior cholecystitis 
Lichen planus, gastro-oesophageal reflux, asthma, 
osteoarthritis 
Omeprazole, methotrexate, folic acid, amitriptyline, 
citalopram, MST, salbutamol 
19 19 Biliary colic ─ ─ 
20 20 Presumed malignancy Prostate cancer ( prostatectomy 2011) ─ 
21 21 Prior CBD calculi 2011 thyroidectmy Graves disease Thyroxine 
22 22 Presumed malignancy Aortic stenosis ─ 
23 23 Prior cholecystitis ─ ─ 
24 24 Biliary colic Segment 5 liver focal nodular hyperplasia ─ 
25 25 Biliary colic Laparotomy malrotation (child) ─ 
26 26 Biliary colic Narcolepsy, epilepsy Lamotrigine, Modafinil 
27 27 Presumed malignancy HTN, pancreatitis Simvastatin, lisinopril, desloratidine, aspirin, metformin 
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Sample Code 
Operative Indication Past medical history Drug history 
BR BU 
28 28 Duodenal tumour upper gastrointestinal bleed ─ ─ 
29 29 Prior cholecystitis (incidental splenic lesion) ─ ─ 
30 30 Biliary colic ─ ─ 
31 31 Biliary colic ─ ─ 
32 32 Biliary colic Hyperthyroid Carbimazole 
33 33 Presumed malignancy ─ ─ 
34 34 Acute pancreatitis ─ ─ 
35 35 Presumed malignancy Myocardial infarct, COPD ─ 
36 36 Chronic pancreatitis. CBD stricture recurrent cholangitis Chronic pancreatitis (ETOH) recurrent CBD stents ─ 
37 37 Prior cholecystitis HTN Amlodiopne, bisoprolol, ramipril 
38 38 Presumed malignancy ─ 
 
39 39 Prior cholecystitis HTN Atenolol, bendroflumethiazide 
40 No urine Prior cholecystitis ─ ─ 
41 41 Prior cholecystitis ─ ─ 
42 42 Biliary colic ─ ─ 
43 43 Biliary colic ─ ─ 
44 44 Presumed malignancy ─ Citalopram 
45 45 Prior CBD calculi ─ ─ 
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Table 2-5 Cancer versus benign cohort age and sex variation 
 
 
Cancer 
(n=44) 
Benign 
(n=45) 
Statistical Significance 
(p) 
Age (yrs) mean +/- SD 65.9 +/- 9.7 52.3 +/- 18.3 0.0001 
Sex M/F 27/17 19/26 0.0908 
 
2.3 Sample collection and processing 
A 5 ml blood sample was collected into a Lithium Heparinised tube via a 
venous cannula inserted for the purpose of general anaesthesia in each 
patient. A 5 ml urine sample was obtained from a urinary catheter placed for 
clinical need among major pancreatic resection patients. Patients managed 
without urinary catheter were asked to provide a sample pre-operatively.  
All samples were processed within one-hour of collection. Blood samples 
were centrifuged at 2000 rpm for ten-minutes. The plasma was removed 
from the sample and stored in eppendorf tubes at -80°C prior to NMR data 
acquisition.  Urine was transferred into eppendorf tubes and similarly stored 
at -80°C.   
2.3.1 NMR sample preparation 
Chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, Dorset, 
UK), unless otherwise stated. NMR tubes (S-5-500-7, Norell) were 
purchased from GPE Scientific Ltd. (Leighton Buzzard, Bedfordshire, UK). 
2.3.1.1 Plasma samples 
Individual samples were returned to room temperature (20°C) and 
centrifuged (Hettich Mikro 120 (C1204) centrifuge, angle rotor A1242) at 
3000 rpm (11,992g) for one-minute to remove any sediment. 300 µL of 
plasma was added to 350 µL of deuterium oxide (D2O). The mixture was 
vortexed for 8 seconds before transferring 600 µL into a 5 mm NMR tube. 
Samples were prepared individually to minimise any on-going metabolism 
prior to analysis.  
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2.3.1.2 Urine samples 
Individual samples were returned to room temperature (20°C) and 
centrifuged (Hettich Mikro 120 (C1204) centrifuge, angle rotor A1242) at 
11,992g for 5 minutes. 460 µl of urine supernatant was added to 230 µL of 
phosphate buffer solution. The urine/phosphate buffer mixture was vortexed 
for 8 seconds before transferring 600 µL to a 5 mm NMR tube. 
100 ml of phosphate buffer solution (pH 7.43) contained 2.885 g sodium 
phosphate dibasic (Na2HPO4), 0.525 g sodium phosphate monobasic 
(NaH2PO4), 0.0172 g (1 mM) trimethylsilyl propanoic acid (TSP) and 0.0195 
g (3 mM) sodium azide (NaN3) in 20 ml of D2O and 80 ml of ribonuclease 
(RNase) free water. The phosphate buffer was shaken thoroughly until salts 
dissolved.  
2.4 NMR data collection 
All 1H-NMR spectra were acquired on a Varian Unity Inova 500 spectrometer 
(Varian Inc, Palo Alto, California, USA) operating at 499.97 MHz proton 
frequency, at 20°C.  
2.4.1 Carr-Purcel-Meiboom-Gill (CPMG) experiment 
The CPMG pulse sequence [RD - 90° - (Ʈ  - 180° - Ʈ )n – acq] was used to 
obtain metabolic profiles of plasma samples. A relaxation delay (RD) of 2 s, Ʈ  
1.5 ms and n of 150 was used for data collection. For each spectrum 512 
transients were collected into 16,284 pairs of data points with a spectral 
width of 8,000.00 Hz.    
2.4.2 1D Nuclear Overhauser effect spectroscopy  (NOESY) experiment 
The one-dimensional (1D) NOESY pulse sequence [RD - 90° - t1 - 90° - tm - 
90° - acq] was used to obtain metabolic profiles for all urine samples. A RD 
of 2 s, tm of 1.5ms and t1 of 3 µs was used for data collection. For each 
spectrum 512 transients were collected into 16,284 pair of data points with a 
spectral width of 8,000.00 Hz. 
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2.4.3 NMR spectral processing 
All spectra were processed using ACD Labs software 12.01 (Advanced 
Chemistry Development, Inc., (ACD/Labs), Toronto, Canada). An 
exponential line broadening (1 Hz) was applied to each free induction decay 
(FID) prior to zero filling to 65,536 (plasma) and 131,072 points for urine. The 
resulting spectra were phased, baseline corrected and referenced. Plasma 
spectra were referenced to the α-glucose (1H chemical shift 5.23 ppm) and 
urine to TSP at 0.000 ppm.  
2.5 Chemometric analysis of plasma spectra  
2.5.1 Binning and dark regions 
Prior to binning over a spectral range, several dark regions were created 
within plasma spectra. Dark regions are areas with an integral set to zero to 
exclude specific variables from subsequent multivariate analysis. These 
included water (4.20-5.70 ppm) and glucose (3.18-3.94 ppm) within plasma 
and water (4.50 – 6.20 ppm) and creatinine (3.034-3.064, 4.043-4.073) within 
urine spectra. Spectral binning was performed using ACD Labs software 
12.01. All spectra were integrated into bins of 0.005 ppm using the intelligent 
bucketing process with a 50% looseness of width. The intelligent bucketing 
process limits spectra division between peaks and thus reduces the risk of 
metabolite loss. 
2.5.2 Multivariate analysis 
All spectra were mean centred and Pareto-scaled using SIMCA-P+ software 
version 12.0.1.0 (Umetrics, Umeå, Sweden).  PCA was performed to view 
any clustering or outliers in the scores plots. Loadings plots were used to 
identify regions of the spectra (bins) responsible for scores plot clustering. 
PLS-DA was performed to improve distinction of separation between groups 
of interest and produce models for validation purposes. The quality of each 
model was assessed by goodness of fit (R2 X) and the ability to predict class 
membership of a new sample (Q2 Y). Model predictive ability was assessed 
by permutation testing and leave-one-out cross validation.  
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3 Results of NMR analysis 
3.1 Analysis of plasma 
This chapter describes the 1H-NMR spectroscopic analysis of plasma 
obtained from 44 patients with confirmed pancreaticobiliary cancer and 45 
patients with benign pancreaticobiliary disease. Among those with confirmed 
cancer, one plasma specimen was spoiled during pre-processing (CR4) and 
ethical considerations and timing prohibited further sample collection. Among 
the benign cohort three patients (BR5, BR7 and BR13) failed to provide 
samples. A total of 43 and 42 confirmed cancer and benign patient samples 
respectively were analysed via 1H-NMR using the CPMG pulse sequence as 
described in section 2.4.1.  
Multivariate analysis was performed as described in section 2.5 in an attempt 
to identify possible biomarkers for pancreaticobiliary malignancy.  
3.1.1 Principle component analysis of the whole plasma dataset 
A PCA model for the whole sample cohort produced six PC‟s. The scores 
plot of PC 1 versus PC 2 is displayed in Figure 3.1. For visualisation 
purposes the CR samples are highlighted blue and the BR samples green. 
The goodness of fit (R2X(cum), the fraction of the sum of squares of all the 
X-variables that are explained by the model) is 0.83. The predictive ability 
(Q2Y(cum), the fraction of the total variation of the X-variables that can be 
predicted by the model) is 0.695. A difference of more than 0.3 between R2X 
and Q2Y is indicative of a poor model due to either noise or outlying data 
points. Five CR samples (CR1, CR12, CR13, CR20 and CR 38) lie outside of 
Hotelling‟s T2 confidence interval. Reviewing the medical records of these 
patients (Table 2-2 and Table 2-4) failed to identify any explanation for the 
outlying nature of sample CR12. Patient CR20 had however within one-
month undergone colorectal surgery (subtotal colectomy) for Duke‟s B 
sigmoid and ascending colon carcinoma which may well account for the 
variation in metabolome. Of interest patients CR1, CR13, and CR38 were all 
taking levothyroxine for hypothyroidism. Of note patients CR43 and BR21 
  
52 
 
were also taking levothyroxime however both are clustered with other BR 
and CR samples.  
 
Figure 3.1 PCA scores plot for all 43 cancer (blue) and 42 benign (green) 
plasma samples showing the first two model components. R2X = 0.406 and 
0.147, and Q2Y = 0.385 and 0.196 for PC 1 and PC 2, respectively 
 
Through focusing on samples lying within the 95% confidence interval the 
BR samples appear to be cluster together toward the left hand side of the 
scores plot. In contrast the CR samples appear to cluster within two discrete 
areas on the scores plot. CR clusters 1 and 2 are surrounded by black 
ellipses for ease of viewing alone (Figure 3.2). Three BR samples, BR2, BR6 
and potentially BR15, although within the 95% confidence interval appear 
separate from the main BR cluster. Upon further clinical review, BR6 
although simplistically classed as benign is actually pre-malignant with final 
histology that of IPMN with moderate dysplasia. Histology from patient BR2 
identified type 2 autoimmune pancreatitis, a rare form of pancreatitis which 
may mimic the clinical presentation of pancreatic cancer. Patient BR2 was 
also of Pakistani ethnicity as opposed to the predominantly Caucasian 
CR20 
CR38 
CR1 
CR13 
CR12 
BR15 
BR2 
BR6 
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patients recruited. Ethnicity is a known confounding factor in metabonomics 
and will be accounted for in subsequent analysis (138).  
 
Figure 3.2 PCA scores plot for all 43 cancer and 42 benign plasma samples 
displaying the first two PC and highlighting clustering of benign (green) and 
malignant (blue) samples 
 
3.1.2 Principle component analysis for potential confounding variables 
In further PCA scores plots there is an attempt to account for true separation 
between CR and BR samples through testing for potential variables such as 
sex, ethnicity, pre-operative serum bilirubin, tumour type, resectability, 
tumour aggressiveness (recurrence and survival data) and the potential 
effect of various subgroups within the “benign” patient cohort such as 
gallstones, chronic pancreatitis, autoimmune pancreatitis, benign and pre-
malignant pancreatic cystic lesions.  
3.1.2.1 Ethnicity as a potential confounding factor 
As displayed in Table 2-1 and Table 2-3 the majority of both the BR and CR 
patients are of Caucasian origin. Among the CR cohort one patient (CR13) is 
of Pakistani origin along with three patients in the benign cohort (BR2, BR30 
BR Cluster 
CR Cluster 1 
CR Cluster 2 
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and BR32). Sample BR2, as described in section 3.1, although within the 95% 
confidence interval is separated away from the main BR cohort. CR13 is 
located outside of the 95% confidence interval. In contrast BR30 and BR32 
appear within the main BR cluster on the scores plot. Options for subsequent 
analysis are to either exclude CR13 and BR2 alone (based on ethnicity and 
potential levothyroxine use for CR13 and ethnicity and histology for BR2) or 
to exclude all four patients. Given that the remainder of the study population 
were of European ethnicity a decision was made to restrict subsequent 
analysis to the European population given the known confounding factor of 
ethnicity in metabonomics (138). 
3.1.2.2 Benign cohort variation as a confounding factor 
As described in section 3.1.1 variation exists with respect to final histological 
diagnosis within the BR cohort. The majority of samples were collected from 
patients with gallstones disease (n=31). Other patients were however 
recruited following pancreatic cystic lesion excision for dysplasia (n=4), 
benign pancreatic lesion resection (n=6), pancreaticojejunostomy for chronic 
pancreatitis (n=2), duodenal resection for GIST (n=1) and open excision of 
retroperitoneal paraganglionoma (Table 2-1 and Table 2-3). This clearly adds 
potential confounding factors to comparative analysis with a heterogeneous 
control group. This is demonstrated, as described in section 3.1.1 by the two 
samples, BR6 and BR2, which are seen to be separate from the main cluster 
of BR samples. BR2 having type 2 AIP and BR6 IPMN with moderate 
dysplasia on final histology.  To assess for further potential variation within 
the BR cohort patients were further classified as either having pure benign or 
pre-malignant histology (Table 2-3). Of those with plasma available for 
analysis a total of five patients were classified as pre-malignant, four patients 
with IPMN (BR6, BR8, BR20 and BR33) and one who underwent duodenal 
resection for GIST (BR33). Interestingly upon constructing a PCA scores plot 
(Figure 3.3) highlighting benign BR (green), pre-malignant (blue) and cancer 
CR (red), despite marked heterogeneity in final histology only one sample 
(BR6), a PPPD for side branch IPMN with low and moderate dysplasia 
appeared markedly dissimilar to the main cluster of benign samples (green). 
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Options at this point are to either exclude sample BR6 alone or the 
remainder of the samples with pre-malignant histology. A decision was made 
to exclude all pre-malignant samples so as to compare true benign versus 
malignant patient metabolome. Insufficient patients were recruited into the 
study for meaningful subgroup analysis of pre-malignant plasma as a 
separate entity. Despite heterogenicity within the benign cohort a decision 
was made to include both patients with gallstone disease along with other 
benign pathology. This was to achieve comparable patient numbers, to 
reflect clinical practice (as patients rarely present with either gallstones or 
malignancy) and due to similar distribution on the scores plot.  
 
Figure 3.3 PCA scores plot of plasma data for 34 benign (green), 5 pre-
malignant (blue) and 42 cancer (red) samples showing the first two PC‟s 
among a European based population 
 
The resulting PCA scores plot for benign versus cancer plasma (excluding 
pre-malignant samples) among a European Population is shown in Figure 
3.4. A total of thirty-four benign and forty-two cancer plasma patients were 
included in each group for analysis. The benign samples remained clustered 
towards the left hand side of the scores plot (BR cluster) and the cancer 
BR6 
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plasmas separated into two clusters (CR cluster 1 and 2). Benign samples 
BR 1 and BR 15 appeared separated from the main benign cluster. Upon 
review no obvious past medical, operative or histological explanation could 
be found to explain this variation.   
 
Figure 3.4 PCA scores plot of plasma data for 42 cancer (blue) and 34 
benign (green) samples displaying the first two PC‟s among a European 
based population with pre-malignant condition exclusion. R2X = 0.379 and 
0.162, and Q2Y = 0.36 and 0.201 for PC 1 and PC 2, respectively 
 
The goodness of fit (R2X(cum), the fraction of the sum of squares of all the 
X-variables that are explained by the model) is 0.751. The predictive ability 
(Q2Y(cum), the fraction of the total variation of the X-variables that can be 
predicted by the model) is 0.609. A difference of more than 0.3 between R2X 
and Q2Y is indicative of a poor model due to either noise or outlying data 
points.   
3.1.2.3 Age and sex as confounding factors 
Among the European patient cohort patients with benign disease were 
younger with a mean age of 51.4 versus 65.3 years (Table 2-5). Variability in 
sex was found to be statistically insignificant (p=0.1657). 
BR Cluster CR Cluster 2 
CR Cluster 1 
BR15 
BR1 
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The PCA scores plot in Figure 3.5 demonstrates that the clustering of cancer 
patients between clusters 1 and 2 is not obviously due to sex.  
 
Figure 3.5 PCA scores plot of plasma data for 15 male (green) and 15 
female (blue) benign and 26 male (red) and 16 female (yellow) cancer 
samples among a European based population with pre-malignant condition 
exclusion. The first two PC‟s are displayed 
 
3.1.2.4 Cancer subtype and resectability as confounding factors 
Cancer resectability does not appear to account for the separation of cancer 
plasma between clusters 1 and 2 (Figure 3.6). For cancer subtype, patients 
with both PDA (n=24) or “other” (n=18) cancer subtypes were seen to reside 
within both CR cluster 1 and 2. There was however a trend towards greater 
separation among the PDA cohort (Figure 3.7).  
BR Cluster CR Cluster 2 
CR Cluster 1 
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Figure 3.6 PCA scores plot of plasma data for 34 benign (green), 27 
resected (blue) and 15 palliative (red) cancer patient samples among a 
European based population with pre-malignant condition exclusion. The first 
two PC‟s are displayed 
 
Figure 3.7 PCA scores plot of plasma data for 34 benign (green), 24 PDA 
(blue) and 18 “other” (red) cancer samples among a European based 
population with pre-malignant condition exclusion. The first two PC‟s are 
displayed 
 
BR Cluster CR Cluster 2 
CR Cluster 1 
CR Cluster 1 
CR Cluster 2 
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3.1.2.5 Plasma bilirubin as a confounding factor 
Patients among the benign cohort had significantly lower plasma bilirubin 
levels pre-operatively than those with malignant disease (Table 3-1). A PCA 
scores plot highlighting cancer sample pre-operative bilirubin (micromol/L) 
variation is displayed in Figure 3.8. All cancer patients with a pre-operative 
plasma bilirubin greater than 40 micromol/L can be found towards the right-
hand side of the scores plot whereas those with pre-operative bilirubin < 20 
micromol/L appear to more closely resemble patients within the benign 
cohort. Figure 3.9 displays a cohort of benign samples and cancer samples 
with a pre-operative bilirubin < 20 and Figure 3.10 a cohort of benign 
samples and cancer samples with a pre-operative bilirubin  > 40 micromol/L.  
 
Table 3-1 Pre-operative plasma bilirubin (micromol/L) for benign and 
malignant samples among a European population with pre-malignant 
condition exclusion 
 
 
Cancer (n=42) Benign (n=34) P 
Pre-op 
bilirubin 
(micromol/L) 
Mean +/- SD 
29.1 +/- 32.9 9.3 +/- 4.8 0.0007 
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Figure 3.8 PCA scores plot of plasma data for 34 benign (green) patients, 
cancer samples with pre-operative plasma bilirubin < 20 (dark-blue), bilirubin 
20-30 (red), 30-40 (yellow) and > 40 micromol/L (light-blue) among a 
European based population with pre-malignant condition exclusion 
 
Figure 3.9 PCA scores plot of plasma data for 34 benign (green) and 33 
cancer (blue) samples with a pre-operative bilirubin < 40 micromol/L among 
a European based population with pre-malignant condition exclusion. The 
first two PC‟s are displayed. R2X = 0.379 and 0.162, and Q2Y = 0.36 and 
0.201 for PC 1 and PC 2, respectively 
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Figure 3.10 PCA scores plot of plasma data for 34 benign (green) and 9 
cancer (blue) samples with a pre-operative bilirubin > 40 micromol/L among 
a European based population with pre-malignant condition exclusion. The 
first two PC‟s are displayed. R2X = 0.335 and 0.184, and Q2Y = 0.311 and 
0.2 for PC 1 and PC 2, respectively 
 
3.1.3 PLS-DA and OPLS plasma analysis 
Based on the findings from initial PCA analysis as described in section 3.1.2, 
subsequent PLS-DA and OPLS analysis will be performed on a sample 
cohort of benign and cancer plasma among the European population with 
pre-malignant sample exclusion. Further analysis will also be performed on 
separate cohorts of European patients with a pre-operative bilirubin of either 
less-than or greater than 40 micromol/L. The PCA scores plots are displayed 
in Figure 3.4, Figure 3.9 and Figure 3.10 respectively.   
3.1.3.1 PLS-DA analysis of benign and cancer plasma among the 
European population with pre-malignant sample exclusion 
A PLS-DA model for the benign and cancer European plasma cohort with 
pre-malignant exclusion is displayed in Figure 3.11 by a two-component 
model.  
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Figure 3.11 PLS-DA scores plot of plasma data for 34 benign and 42 cancer 
samples in a European population with pre-malignant exclusions. R2X (cum) 
= 0.516, R2Y (cum) = 0.44 and Q2Y (cum) = 0.319 
 
Five samples (CR1, CR8, CR12, CR20 and CR38) in Figure 3.11 lie at or 
beyond Hotelling‟s T2 confidence interval. As described in section 3.1.1 
patient numbers CR1 and CR38 were both taking prescription medication 
(levothyroxine) for hypothyroidism. Patient CR20 had within one month 
undergone subtotal colectomy for ascending and sigmoid colon 
adenocarcinoma. No obvious factor within the past medical or prescription 
history for patients CR8 and CR12 could be identified to account for 
significant metabolic variance. Following exclusion of extreme outliers (CR1, 
CR8, CR12, CR20 and CR38) a repeat PLS-DA model is generated and 
displayed in Figure 3.12 by a single component model.  
CR20 
CR38 
CR8 
CR12 CR1 
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Figure 3.12 PLS-DA single component model for benign n=34 (green) and 
cancer n=37 (blue) plasma samples among a European population with pre-
malignant and extreme outlier exclusion. R2X (cum) = 0.318, R2Y (cum) = 
0.354 and Q2Y (cum) = 0.308 
 
3.1.3.1.1 Permutation testing of PLS-DA model 
Permutation testing demonstrates how a model in which the Y-variables 
(class membership) are randomised compare to the original PLS-DA model. 
For the PLS-DA model displayed in Figure 3.12, all permutated R2 and Q2 
values to the left were lower than the original points to the right, and lower 
than the original values. This indicates model validity with respect to both 
benign (Figure 3.13) and cancer sample  (Figure 3.14) permutation.  
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Figure 3.13 Permutation testing plot for the PLS-DA model shown in Figure 
3.12. Thirty-six permutations selected with reference to thirty-four benign 
samples within the model. R2Y = 0.0977 and Q2Y -0.0842 
 
 
Figure 3.14 Permutation testing plot for the PLS-DA model shown in Figure 
3.12. Thirty-nine permutations selected with reference to thirty-seven cancer 
samples within the model. R2Y = 0.105 and Q2Y -0.109 
 
R2 
Q2 
R2 
Q2 
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3.1.3.1.2 Cross validation of PLS-DA models 
Cross validation of PLS-DA or OPLS models may be achieved in a number 
of ways, including by testing if new additional samples are correctly classified. 
As no further appropriate samples were available it was decided to internally 
validate by sequentially removing one-third of cancer and benign data sets - 
building a model on the remaining two-thirds of samples and testing how the 
“removed” one-third are classified when re-introduced (Table 3-2). The 
resulting model sensitivity, specificity and predictive values are displayed 
(Table 3-3). 
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Table 3-2 Cross validation of the model displayed in Figure 3.12 
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively 
 
Sample 
Y Predicted* 
 
Sample 
Y Predicted* 
 
Sample 
Y Predicted* 
Benign Cancer 
 
Benign Cancer 
 
Benign Cancer 
BR1 0.91 0.09 
 
BR18 0.85 0.15 
 
BR34 0.93 0.07 
BR3 0.74 0.26 
 
BR19 0.88 0.12 
 
BR35 0.42 0.58 
BR4 0.67 0.33 
 
BR21 0.72 0.28 
 
BR36 0.31 0.69 
BR9 0.61 0.39 
 
BR22 0.58 0.42 
 
BR37 0.93 0.07 
BR10 0.49 0.51 
 
BR23 0.73 0.27 
 
BR38 0.45 0.55 
BR11 0.63 0.37 
 
BR24 0.83 0.17 
 
BR39 0.87 0.13 
BR12 0.30 0.70 
 
BR25 0.84 0.16 
 
BR40 0.78 0.22 
BR14 0.53 0.47 
 
BR26 0.92 0.08 
 
BR41 0.74 0.26 
BR15 -0.10 1.10 
 
BR27 0.44 0.56 
 
BR42 0.92 0.08 
BR16 0.68 0.32 
 
BR29 0.85 0.15 
 
BR43 0.92 0.08 
BR17 0.38 0.62 
 
BR31 0.90 0.10 
 
BR44 0.33 0.67 
CR2 0.37 0.63 
 
CR18 0.46 0.54 
 
BR45 0.85 0.15 
CR3 0.19 0.81 
 
CR19 0.30 0.70 
 
CR31 0.40 0.60 
CR5 0.15 0.85 
 
CR21 0.43 0.57 
 
CR32 -0.03 1.03 
CR6 0.55 0.45 
 
CR22 0.67 0.33 
 
CR33 0.46 0.54 
CR7 0.18 0.82 
 
CR23 0.28 0.72 
 
CR34 0.71 0.29 
CR9 0.06 0.94 
 
CR24 0.53 0.47 
 
CR35 0.37 0.63 
CR10 0.23 0.77 
 
CR25 0.87 0.13 
 
CR36 0.55 0.45 
CR11 0.26 0.74 
 
CR26 0.32 0.68 
 
CR37 0.34 0.66 
CR14 0.20 0.80 
 
CR27 0.51 0.49 
 
CR39 0.32 0.68 
CR15 0.09 0.91 
 
CR29 0.80 0.20 
 
CR40 0.64 0.36 
CR16 0.44 0.56 
 
CR28 0.57 0.43 
 
CR41 0.68 0.32 
CR17 0.38 0.62 
 
CR30 0.88 0.12 
 
CR42 0.62 0.38 
   
     
CR43 0.25 0.75 
        
CR44 0.34 0.66 
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Table 3-3 Model sensitivity, specificity, positive and negative predictive 
values 
 
Test Cancer 
 Present (37) Absent (34) Total 
Positive True positive (24) False positive (9) 33 
Negative False negative (13) True negative (25) 38 
 
 
% 95% C.I 
Sensitivity 64.9 47.5-79.8 
Specificity 73.5 55.64-87.1 
Positive predictive value 72.7 54.5-86.7 
Negative predictive value 65.8 48.6-80.3 
 
3.1.3.1.3 OPLS loading plot and metabolite identification 
A loading plot generated through OPLS from the model shown in Figure 3.12 
is displayed in Figure 3.15. The loadings pq plot is a superimposition of the p 
plot and the q plot, for the first component of the OPLS model. The loading 
vector p1 corresponds to the co-variances between the X-variables and the 
score vector t1, whereas the loading vector q1 expresses the importance of 
the variables in approximating Y variation correlated to X, in the first 
component. The X-axis on the loadings plot corresponds with the X-axis (in 
ppm) on the NMR spectrum. Variation in the loadings plot can therefore be 
directly related to the NMR spectrum and hence metabolite identification. 
Distribution above zero on the Y-axis in Figure 3.15 represents up-regulation 
of signal among cancer samples and vice versa.  
Due to the use of the intelligent bucketing process for spectral binning (to 
minimize metabolite loss) the resultant OPLS loadings plots fail to align 
perfectly with the original NMR spectra.  
  
68 
 
 
Figure 3.15 OPLS Loadings plot for the model displayed in Figure 3.12 
 
The loadings plot shown in Figure 3.15 is magnified to highlight chemical 
shift range 0.9 – 2.1 ppm (Figure 3.16). The corresponding region on a 
cancer NMR spectrum (CR16 as an example) is magnified in Figure 3.17. 
Example metabolites are highlighted in both Figure 3.16 and Figure 3.17 
through reference to a NMR database of plasma metabolite chemical shifts 
and peak multiplicity (139). 
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Figure 3.16 OPLS Loadings plot for the model displayed in Figure 3.12 with 
expansion of 0.8–2.0 ppm chemical shift 
 
 
Figure 3.17 NMR spectrum for sample CR16 with expansion of chemical 
shift 0-2.5 ppm 
RS-CR16-150113.esp
Chemical Shift (ppm)2.0 1.5 1.0 0.5 0
0
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
0.0007
0.0008
0.0009
Acetate 1.91 ppm 
Acetate 1.91 ppm 
VLDL 0.87 ppm 
VLDL 1.29 ppm 
VLDL 0.87 ppm 
VLDL 1.29 ppm 
Lactate 1.33 ppm 
Lactate 1.33 ppm 
3-hydroxybutyrate 1.20 ppm 
3-hydroxybutyrate 1.20 ppm 
Isobutyrate 1.13 ppm 
Isobutyrate 1.13 ppm 
Valine 1.02 ppm Valine 0.97 ppm 
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Figure 3.18 OPLS Loadings plot for the model displayed in Figure 3.12 with 
expansion of 1.8–3.0 ppm chemical shift 
 
 
Figure 3.19 OPLS Loadings plot for the model displayed in Figure 3.12 with 
expansion of 3.0–4.5 ppm chemical shift 
Acetate 1.91 ppm 
Acetoacetate 2.22 ppm 
Pyruvate 2.37 ppm 
Taurine 3.25/ α-Glucose 
3.42 ppm  
Taurine 3.41 ppm/ Β-Glucose 
3.4 ppm 
Β-Glucose 3.90 ppm 
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Figure 3.20 NMR spectrum for sample CR16 with expansion of chemical 
shift 1.9-4.5 ppm 
 
A summary of the assigned metabolites across the entire spectral range is 
displayed within Table 3-3. Region A as displayed in Figure 3.20 is 
particularly complex making it difficult to unambiguously assign metabolites 
by 1D-NMR.  
 
 
 
 
 
 
 
 
RS-CR16-150113.esp
Chemical Shift (ppm)4.5 4.0 3.5 3.0 2.5
0
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
0.0007
0.0008
0.0009
0.0010
Acetate 191 ppm 
Acetoacetate 2.22 ppm 
Pyruvate 2.37 ppm 
Β-Glucose 3.90 ppm 
Taurine 3.25/ α -Glucose 
3.42 ppm 
Taurine 3.41 ppm 
Region A 
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Table 3-4 Metabolite identification for model displayed in Figure 3.12 
 
H chemical shift 
(ppm) 
Multiplicity Metabolite 
Metabolite 
change in 
cancer 
0.87 t Lipid (mainly VLDL) ↓ 
0.97 d Valine ↓ 
1.02 d Valine ↓ 
1.13 d Isobutyrate ↑ 
1.2 d 3-hydroxybutyrate ↑ 
1.29 m Lipid (mainly VLDL) ↓ 
1.33 d Lactate ↑ 
1.91 m Acetate ↓ 
2.22 s Acetoacetate ↑ 
2.37 s Pyruvate ↑ 
3.25/3.42 t Taurine/ α-glucose* ↑ 
3.40/3.41 t β-glucose/Taurine* ↑ 
3.9 dd β-glucose ↑ 
*2D-NMR required to confirm metabolite assignment 
 
3.1.3.2 PLS-DA analysis of benign and cancer plasma with a pre-
operative bilirubin less than 40 micromol/L 
A PLS-DA model for benign and cancer plasma samples among a European 
population with a pre-operative bilirubin of less-than 40 micromol/L with pre-
malignant exclusion is displayed below (Figure 3.21). One sample (CR1) was 
excluded as an extreme outlier. The PLS-DA model generated was 
explained by a single component (Figure 3.22).   
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Figure 3.21 PLS-DA scores plot of plasma data for 34 benign (green) and 33 
cancer (blue) samples with a pre-operative bilirubin of less-than 40 
micromol/L with pre-malignant exclusions. R2X (cum) = 0.311, R2Y (cum) = 
0.32 and Q2Y (cum) = 0.265 
 
Figure 3.22 PLS-DA scores plot of plasma data for 34 benign (green) and 32 
cancer (blue) samples with a pre-operative bilirubin of less than 40 
micromol/L with exclusions. R2X (cum) = 0.272, R2Y (cum) = 0.348 and Q2Y 
(cum) = 0.302 
 
CR1 
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3.1.3.2.1 Permutation testing of PLS-DA model 
Validity of the model displayed in Figure 3.22 was demonstrated through 
permutation of both benign (Figure 3.23) and cancer (Figure 3.24) sample 
class membership. 
  
Figure 3.23 Permutation testing plot for the PLS-DA model shown in Figure 
3.22. Thirty-six permutations selected with reference to thirty-four benign 
samples within the model. R2Y = 0.111 and Q2Y = -0.0954 
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Figure 3.24 Permutation testing plot for the PLS-DA model shown in Figure 
3.22. Thirty-four permutations selected with reference to thirty-two cancer 
samples within the model. R2Y = 0.108 and Q2Y = -0.111 
 
3.1.3.2.2 Cross section model validation 
Cross validation of the model is performed (Table 3-5) as described in 
section 3.1.3.1.2 for the PLS-DA model displayed in Figure 3.22. The 
resultant sensitivity and specificity of the model is displayed in Table 3-6. 
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Table 3-5 Cross validation of the model displayed in Figure 3.22 
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively. 
Class allocation was not possible for sample BR10 (blue) 
 
Sample 
Y predict     Y predict     Y predict 
Benign Cancer   Sample Benign Cancer   Sample Benign Cancer 
BR1 0.95 0.05   BR19 0.97 0.03   BR35 0.41 0.59 
BR3 0.8 0.2   BR21 0.82 0.18   BR36 0.22 0.78 
BR4 0.7 0.3   BR22 0.55 0.45   BR37 0.95 0.05 
BR9 0.64 0.36   BR23 0.75 0.25   BR38 0.34 0.66 
BR10 0.5 0.5   BR24 0.9 0.1   BR39 0.92 0.08 
BR11 0.66 0.34   BR25 0.9 0.1   BR40 0.78 0.22 
BR12 0.33 0.67   BR26 0.98 0.02   BR41 0.72 0.28 
BR14 0.55 0.45   BR27 0.3 0.7   BR42 0.95 0.05 
BR15 -0.01 1.01   BR29 0.87 0.13   BR43 0.94 0.06 
BR16 0.7 0.3   BR31 0.87 0.13   BR44 0.19 0.81 
BR17 0.41 0.59   BR34 1.03 -0.03   BR45 0.93 0.07 
BR18 0.74 0.26   CR24 0.45 0.55   CR35 0.23 0.77 
CR10 0.27 0.73   CR25 0.95 0.05   CR36 0.44 0.56 
CR2 0.42 0.58   CR26 0.21 0.79   CR37 0.22 0.78 
CR7 0.28 0.72   CR27 0.4 0.6   CR38 0.27 0.73 
CR14 0.26 0.74   CR28 0.39 0.61   CR39 0.19 0.81 
CR16 0.48 0.52   CR29 0.85 0.15   CR40 0.54 0.46 
CR17 0.39 0.61   CR30 0.81 0.19   CR41 0.64 0.36 
CR18 0.16 0.84   CR31 0.31 0.69   CR42 0.67 0.33 
CR19 0.34 0.66   CR32 -0.2 1.2   CR43 0.14 0.86 
CR20 -0.1 1.1   CR33 0.47 0.53   CR44 0.19 0.81 
CR21 0.25 0.75   CR34 0.69 0.31 
    CR22 0.55 0.45 
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Table 3-6 Model sensitivity, specificity, positive and negative predictive 
values 
 
Test 
Cancer 
Total 
Present (32) Absent (34) 
Positive True positive (24) False positive (8) 32 
Negative False negative (8) True negative (25) 33 
 
  % 95% C.I 
Sensitivity 75 56.6-88.5 
Specificity 75.8 57.7-88.9 
Positive predictive value 75 56.6-88.5 
Negative predictive value 75.8 57.7-88.9 
 
3.1.3.2.3 OPLS loading plot and metabolite allocation 
A loadings plot generated through OPLS form the model shown in Figure 
3.22 is displayed below (Figure 3.25). Metabolite allocation for this model is 
described in section 3.1.4. 
 
Figure 3.25 OPLS loadings plot for the model displayed in Figure 3.22 
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3.1.3.3 PLS-DA analysis of benign and cancer plasma with a pre-
operative bilirubin greater than 40 micromol/L 
Nine patients with a bilirubin greater than 40 micromol/L were included into a 
cohort of nine patients with benign disease selected at random. The resulting 
PLS-DA scores plot was explained by a single component (Figure 3.26). 
 
Figure 3.26 PLS-DA scores plot of plasma data for 9 benign (green) and 9 
cancer (blue) samples with a pre-operative bilirubin of greater than 40 
micromol/L with exclusions. R2X (cum) = 0.498, R2Y (cum) = 0.814 and Q2Y 
(cum) = 0.763 
 
3.1.3.3.1 Permutation testing of PLS-DA model 
With an R2Y intercept values of 0.223 and 0.18 and Q2Yvalues of  -0.172 and 
-0.213 with respect to benign and cancer specimens respectively the model 
is valid. 
3.1.3.3.2 Cross section model validation 
Cross validation of the model is performed (Table 3-7) as described in 
section 3.1.3.1.2 for the PLS-DA model displayed in Figure 3.26. The 
resultant sensitivity and specificity of the model is displayed in Table 3-8. 
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Table 3-7 Cross validation of the model displayed in Figure 3.26 
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively 
 
Sample 
Y predicted* 
 
Sample 
Y predicted* 
 
Sample 
Y predicted* 
Benign Cancer 
 
Benign Cancer 
 
Benign Cancer 
BR3 0.75 0.25 
 
BR11 0.88 0.12 
 
BR24 1.00 0.00 
BR9 0.80 0.20 
 
BR19 0.96 0.04 
 
BR43 1.09 -0.09 
BR10 0.79 0.21 
 
BR21 0.79 0.21 
 
BR45 0.95 0.05 
CR3 0.26 0.74 
 
CR8 -0.21 1.21 
 
CR12 -0.47 1.47 
CR5 0.18 0.82 
 
CR9 0.09 0.91 
 
CR15 0.20 0.80 
CR6 0.44 0.56 
 
CR11 0.20 0.80 
 
CR23 0.60 0.40 
 
Table 3-8 Model sensitivity, specificity, positive and negative predictive 
values 
 
Test 
Cancer 
Total 
Present (9) Absent (9) 
Positive True positive (8) False positive (0) 8 
Negative False negative (1) True negative (9) 10 
 
 
% 95% C.I 
Sensitivity 88.9 51.7-98.1 
Specificity 100 66.2-100 
Positive predictive value 100 62.9-100 
Negative predictive value 90 55.5-98.3 
 
3.1.3.3.3 OPLS loadings plot and metabolite allocation 
A loadings plot generated through OPLS form the model shown in Figure 
3.26 is displayed below (Figure 3.27). Metabolite allocation for this model is 
described in section 3.1.4. 
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Figure 3.27 OPLS loadings plot for the model displayed in Figure 3.26 
 
3.1.4 Metabolite comparison for overall benign and malignant samples 
(with exclusions) versus cancer patients with or without pre-
operative jaundice 
OPLS loading plots for overall benign and malignant samples, patients with a 
pre-operative bilirubin less than or equal to 40 micromol/L and patients with 
bilirubin greater than 40 micromol/L are displayed (Figure 3.28). Two regions 
of spectral variation (representing metabolite change) are highlighted (region 
one and two). Expansion of regions one and two along with metabolite 
assignment is displayed within Figure 3.29 and Figure 3.30, respectively. 
 
 
 
 
 
  
81 
 
 
 
 
Figure 3.28 OPLS loading plots for overall benign and cancer samples (A), 
jaundiced (B) and non-jaundiced patients (C) 
 
A 
B 
C 
Region 2 
Region 1 
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Figure 3.29 OPLS loading plots for overall benign and cancer samples (A), 
jaundiced (B) and non-jaundiced patients (C) with expansion of chemical 
shift 0.8-2.0 ppm (Region 1 Figure 3.28) 
 
Acetate 1.91 ppm VLDL 1.29 ppm 
Lactate 1.33 ppm 
3-hydroxybutyrate 1.20 ppm 
  Isobutyrate 1.13 ppm 
Valine 1.02 & 0.97 ppm 
VLDL 0.87 ppm 
  Isobutyrate < A 
No valine discrimination 
No 3-hydroxybutyrate discrimination 
Un-identified metabolite absent in B, 
present A &C 
Increased lactate 
A 
B 
C 
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Figure 3.30 OPLS loading plots for overall benign and cancer samples (A), 
jaundiced (B) and non-jaundiced patients (C) with expansion of chemical 
shift 1.8-3.0 ppm (Region 2 Figure 3.28) 
Acetate 1.91 ppm 
Acetoacetate 2.22 ppm 
Pyruvate 2.37 ppm 
Acetoacetate > A 
Reduced acetoacetate 
A 
B 
C 
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Metabolite allocation in table format is displayed in Table 3-9. 
 
Table 3-9 Metabolite assignment for overall benign and cancer samples 
(with exclusions) and patients with or without pre-operative jaundice 
 
H chemical shift 
(ppm) 
Multiplicity Metabolite 
Metabolite change 
in cancer 
Bil < 
40micromol/L 
Bil > 40 
micromol/L 
0.87 t Lipid (mainly VLDL) ↓ ↓ ↓ 
0.97 d Valine ↓ ↓ NC 
1.02 d Valine ↓ ↓ NC 
1.13 d Isobutyrate ↑ ↑ ↑ 
1.2 d 3-hydroxybutyrate ↑ NC ↑ 
1.29 m Lipid (mainly VLDL) ↓ ↓ ↓ 
1.33 d Lactate ↑ ↑ ↑ 
1.91 m Acetate ↓ ↓ ↓ 
2.22 s Acetoacetate ↑ ↓ ↑ 
2.37 s Pyruvate ↑ ↑ ↑ 
3.25/3.42 t/dd Taurine/β-glucose* ↑ ↑ ↑ 
3.40/3.41 t β-glucose/Taurine* ↑ ↑ ↑ 
3.9 dd β-glucose ↑ ↑ ↑ 
 
 
 
 
 
 
 
 
 
 
 
  
85 
 
3.2 Analysis of Urine 
This chapter describes the 1H-NMR spectroscopic analysis of urine obtained 
from 44 patients with confirmed pancreaticobiliary cancer and 45 patients 
with benign pancreaticobiliary disease. Among those with benign disease, 
three patients (BU3, BU4 and BU40) failed to provide a urine sample. A total 
of 44 and 42 confirmed cancer and benign patient samples respectively were 
subsequently profiled via 1H-NMR using the 1D NOESY pulse sequence. 
Multivariate analysis was performed as described in section 2.5 in an attempt 
to identify potential novel biomarkers for pancreaticobiliary malignancy. 
3.2.1 Principle component analysis of the whole urine cohort 
A PCA model for the whole dataset produced six PC‟s (Figure 3.31). An 
R2X(cum) and Q2Y(cum) of 0.808 and 0.405 respectively is indicative of a 
poor model.   
 
Figure 3.31 PCA scores plot of urine data for all 43 cancer (blue) and 42 
benign (green) samples 
 
BU14 
BU39 
BU32 
CU39 
CU15 
CU28 
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A repeat PCA scores plot with outlier sample exclusion (BU14, BU32, BU39, 
CU18, CU28 and CU39) failed to show clear separation with a R2X(cum) and 
Q2Y(cum) of 0.744 and 0.389 respectively (Figure 3.32).  
 
Figure 3.32 PCA scores plot of urine data for 40 cancer (blue) and 39 benign 
samples 
 
3.2.2 Principle component analysis for potential confounding variables 
In further PCA models separation between samples according to variables 
such as sex, ethnicity, pre-operative serum bilirubin, tumour type and tumour 
respectability is tested. 
3.2.2.1 Ethnicity as a potential confounding factor 
Unlike plasma chemometric analysis as described in section 3.1.2.1, PCA 
modelling failed to highlight any separation of data according to ethnicity with 
an R2X (cum) and (Q2Y(cum) of 0.816 and 0.164 respectively (Figure 3.33). 
Samples BU14 and BU18 appeared as extreme outliers (Figure 3.33). 
Patient BU16 underwent laparoscopic cholecystectomy on a semi-urgent 
basis due to acute pancreatitis. Upon further review patient BU18 was found 
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to have an extensive prescription drug history. Further multivariate analysis 
of urine will include patients of all ethnicity. 
  
Figure 3.33 PCA scores plot of urine data for benign European (green) and 
non-European (blue) urine 
 
3.2.2.2 Benign cohort disease status as a confounding factor 
PCA modelling failed to identify any clear separation between benign or pre-
malignant benign samples with an R2X (cum) and Q2Y(cum) of 0.816 and 
0.164 respectively (Figure 3.34). For subsequent urine meta-analysis both 
benign and pre-malignant urine samples will be considered as a single 
cohort. BU14 and BU16 are obvious outliers for the potential reasons 
described in section 3.2.2.1. 
BU14 
BU18 
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Figure 3.34 PCA scores plot of urine data for benign (green) and pre-
malignant (blue) samples 
 
3.2.2.3 Age and sex as confounding factors 
The patients among the benign urine cohort are younger with a mean age of 
52.1 versus 65.9 years. No statistically significant sex variation was apparent 
(Table 3-12). 
3.2.2.4 Age and sex variation for 44 cancer and 34 benign patients 
 
 
Cancer 
(n=44) 
Benign 
(n=42) 
Statistical Significance 
(p) 
Age (yrs) mean +/- 
SD 
65.9 +/- 9.7 
52.1 +/- 
17.7 
0.0001 
Sex M/F 27/17 19/23 0.1942 
 
PCA modelling failed to highlight any obvious clustering of data within the 
benign cohort according to sex with an R2X (cum) and Q2Y(cum) of 0.816 
and 0.164 respectfully (Figure 3.35). 
BU18 
BU14 
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Figure 3.35 PCA scores plot of data for male (green) and female (blue) 
benign samples 
 
Potential clustering according to sex was identified among the cancer cohort 
on PCA modelling. As displayed in Figure 3.36, male samples appear 
predominantly within cluster 1 and females within cluster 2. With an R2X 
(cum) and Q2Y(cum) of 0.697 and 0.365 respectively, the model does not 
reach validity due to either noise or outlying data points. A repeat PCA model, 
following exclusion of outlying samples (CR15, CR26, CR28 and CR39) 
failed to display any clustering according to sex among the cancer cohort 
with an R2X(cum) and Q2Y(cum) of 0.715 and 0.326 respectively (Figure 
3.37).  
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Figure 3.36 PCA scores plot of urine data for male (green) and female (blue) 
cancer samples 
 
 
Figure 3.37 PCA scores plot of urine data for male (green) and female (blue) 
cancer samples with exclusions 
 
Cluster 1 
Cluster 2 
CU39 
CU28 
CU26 
CU15 
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3.2.2.5 Cancer subtype and resectability 
PCA modelling failed to identify any clustering of data according to cancer 
type (PDA versus other malignancy) with an R2X (cum) and Q2Y (cum) of 
0.808 and 0.405 respectively (Figure 3.38). A repeat model excluding 
outlying samples (BU14, BU32, BU39, CU15, CU28 and CU39) also failed to 
identify obvious clustering of data with an R2X (cum) and Q2Y (cum) of 0.756 
and 0.362 respectively.  
 
Figure 3.38 PCA scores plot of urine data for benign (green), PDA (blue) 
and other CU (red) 
 
PCA modelling failed to identify any obvious clustering of data according to 
cancer resection status (resected or palliative operation) with an R2X (cum) 
and Q2Y(cum) of 0.808 and 0.405 respectively (Figure 3.39). A repeat PCA 
model following extreme outlying sample exclusion also failed to identify any 
clustering of data with an R2X (cum) and Q2Y(cum) of 0.756 and 0.362 
respectively (Figure 3.40). Similarly a PCA scores plot for resectable versus 
irresectable cancer urine (without benign cohort inclusion) also failed to 
reveal any obvious clustering of data with an R2X (cum) and Q2Y(cum) of 
0.697 and 0.365 respectively (Figure 3.41).  
BU39 
BU14 
BU32 
CU39 
CU15 
CU28 
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Figure 3.39 PCA scores plot of urine data for benign (green), resectable 
(blue) and palliative cancer samples. Outlying samples labelled 
 
 
Figure 3.40 PCA scores plot of urine data for benign (green), resectable 
(blue) and palliative cancer samples with outlier exclusions 
 
BU14 
CU39 
CU14 
BU39 
BU32 
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Figure 3.41 PCA scores plot of urine data for resectable (green) and 
palliative (blue) cancer samples 
 
3.2.2.6 Pre-operative bilirubin variation 
PCA modelling of benign samples, cancer samples with a pre-operative 
bilirubin of less than 40 or greater than 40 micromol/L failed to reveal any 
obvious clustering of data with an R2X (cum) and Q2Y(cum) of 0.808 and 
0.405 respectively (Figure 3.42). PCA modelling of cancer urine with a pre-
operative bilirubin less than or equal to 40 versus greater than 40 micromol/L 
(excluding benign cohort) also failed to highlight any separation with an R2X 
(cum) and Q2Y (cum) of 0.697 and 0.365 respectively (Figure 3.43).   
CU15 
CU28 
CU39 CU26 
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Figure 3.42 PCA scores plot of urine data for benign (green), cancer 
samples with pre-operative bilirubin < 40 (blue) and > 40 micromol/L (red) 
 
 
 
Figure 3.43 PCA scores plot of urine data for cancer samples with pre-
operative bilirubin < 40 (blue) and > 40 micromol/L (red) 
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PCA modelling for benign urine samples and cancer patients with a pre-
operative bilirubin less than or equal to 40 micromol/L failed to identify any 
obvious separation with a R2X (cum) and Q2Y(cum) of 0.789 and 0.402 
respectfully (Figure 3.44). A similar scores plot is displayed for urine samples 
with benign disease and cancer patients with a pre-operative bilirubin greater 
than 40 micromol/L with a resulting R2X (cum) and Q2Y(cum) of 0.779 and 
0.269 respectively (Figure 3.45). Given the large discrepancy in the number 
of benign patients (n=42) versus the number of cancer patients with a pre-
operative bilirubin greater than 40 micromol/L (n=10) a separate model with 
random benign sample reduction is shown (Figure 3.46). R2X (cum) and Q2Y 
(cum) for this model is 0.726 and 0.313 respectfully.   
 
Figure 3.44 PCA scores plot of urine data for urine samples with benign 
disease (green) and those with a pre-operative bilirubin of less than or equal 
to 40 micromol/L (blue) 
 
BU14 
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CU39 
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Figure 3.45 PCA scores plot of urine data for urine samples with benign 
disease (green) and those with a pre-operative bilirubin of greater than 40 
micromol/L (blue) 
 
 
Figure 3.46 PCA scores plot of urine data for urine samples with benign 
disease (green) and those with a pre-operative bilirubin of greater than 40 
micromol/L (blue) with random benign reductions 
CU15 
BU32 
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3.2.3 PLS & OPLS-DA analysis of urine samples 
Unsupervised PCA analysis for urine, as described in section 3.2.2 failed to 
identify any potential clustering of either benign or malignant samples within 
principle components one and two. Supervised PLS and OPLS-DA analysis 
has thus been applied to selected cohorts to assess for any separation not 
revealed by PCA analysis alone. 
3.2.3.1 PLS analysis for overall urine data for benign and malignant 
samples 
It was not possible to generate a PLS-DA model using the cohort adopted for 
the PCA in either Figure 3.31 or Figure 3.32.  
3.2.3.2 PLS-DA analysis according to cancer subtype 
A PLS model comparing PDA urine versus “other” cancer urine within the 
cancer cohort is displayed below (Figure 3.47). 
 
Figure 3.47 PLS-DA scores plot of urine data for 25 PDA (green) and 19 
“other” cancer samples (blue). R2X (cum) = 0.31, R2Y (cum) = 0.257 and Q2Y 
(cum) = 0.169 
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The model displayed in Figure 3.47 is poorly fitted and not valid as several of 
the permutated R2Y values (to the left) lie at or above that of the original 
model with respect to both PDA (Figure 3.48) and “other” cancer (Figure 3.49) 
class permutation. 
 
Figure 3.48 Permutation testing plot for the PLS-DA model shown in Figure 
3.47. Twenty-seven permutations selected with reference to twenty-five PDA 
samples within the model. R2Y = 0.244 and Q2Y -0.0745 
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Figure 3.49 Permutation testing plot for the PLS-DA model shown in Figure 
3.47. Twenty-one permutations selected with reference to nineteen “other 
cancer” samples within the model. R2Y = 0.207 and Q2Y -0.0999 
 
The results of an attempt at cross validation through removing a third of 
samples in turn from both the PDA and “other” cancer cohort within the PLS-
DA model is displayed within Table 3-10. The resultant sensitivity and 
specificity of the model is displayed (Table 3-11). 
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Table 3-10 Cross validation of the model displayed in Figure 3.47 
 
Sample 
Y predict 
 Sample 
Y predict 
 Sample 
Y predict 
PDA 
Other 
CU  
PDA 
Other 
CU  
PDA 
Other 
CU 
CU1-PDA -0.11 1.11 
 
CU12-PDA 0.49 0.51 
 
CU31-PDA 0.62 0.38 
CU2-PDA 0.98 0.02 
 
CU14-PDA 0.63 0.37 
 
CU33-PDA 0.23 0.77 
CU3-PDA 0.96 0.04 
 
CU16-PDA 0.60 0.40 
 
CU34-PDA 0.69 0.31 
CU4-PDA 0.50 0.50 
 
CU17-PDA 0.67 0.33 
 
CU35-PDA 0.09 0.91 
CU5-PDA 0.96 0.04 
 
CU22-PDA 0.71 0.29 
 
CU36-PDA 1.10 -0.10 
CU7-PDA 1.24 -0.24 
 
CU23-PDA 0.83 0.17 
 
CU42-PDA 0.56 0.44 
CU8-PDA 0.87 0.13 
 
CU27-PDA 0.59 0.41 
 
CU43-PDA 0.96 0.04 
CU9-PDA 0.71 0.29 
 
CU29-PDA 0.57 0.43 
 
CU44-PDA 0.58 0.42 
CU11-PDA 0.51 0.49 
 
CU21 0.39 0.61 
 
CU32 0.27 0.73 
CU6 0.76 0.24 
 
CU24 0.69 0.31 
 
CU37 1.07 -0.07 
CU10 0.90 0.10 
 
CU25 0.57 0.43 
 
CU38 1.16 -0.16 
CU13 0.24 0.76 
 
CU26 0.41 0.59 
 
CU39 -0.78 1.78 
CU15 -0.04 1.04 
 
CU28 0.02 0.98 
 
CU40 0.62 0.38 
CU18 0.89 0.11 
 
CU30 0.45 0.55 
 
CU41 0.15 0.85 
CU19 0.81 0.19 
        
CU20 0.61 0.39 
        
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively. 
Class membership could not be allocated for sample CU4 
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Table 3-11 Model sensitivity, specificity, positive and negative predictive 
values 
 
Test 
PDA 
Present (32) Absent* (38) 
Positive True positive (20) False positive (10) 
Negative False negative (4) True negative (9) 
 
 
% 95% C.I 
Sensitivity 83.3 
62.6-
95.2 
Specificity 47.4 
24.5-
71.1 
Positive predictive value 66.7 
47.2-
82.3 
Negative predictive value 69.2 
38.6-
90.7 
 
3.2.3.3 PLS-DA for cancer resectability 
It was not possible to generate a PLS-DA model using the cohort adopted for 
the PCA in Figure 3.41. 
3.2.3.4 PLS-DA for bilirubin variation 
A PLS-DA model for benign urine and cancer urine with a pre-operative 
bilirubin less than or equal to 40micromol/L was not possible without 
excluding the outlying samples (BU14, BU18, BU32, BU39, CU28 and CU39) 
which lie beyond the 95% confidence interval in the PCA model (Figure 3.44). 
The resulting PLS-DA model is expressed in a single component (Figure 
3.50). 
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Figure 3.50 PLS-DA scores plot of urine data for 38 benign (green) and 32 
cancer samples with a bilirubin less than or equal to 40micromol/L (blue) with 
outlier exclusions. R2X (cum) = 0.278, R2Y (cum) = 0.229 and Q2Y (cum) = 
0.131 
 
Validity of the model was not confirmed through permutation testing with 
several permuted R2Y values to the left lying above that of the original model 
with respect to both benign (Figure 3.51) and cancer (Figure 3.52) class 
permutation.  
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Figure 3.51 Permutation testing plot for the PLS-DA model shown in Figure 
3.50. Forty permutations selected with reference to thirty-eight benign 
samples within the model. R2Y = 0.171 and Q2Y -0.0846 
 
 
Figure 3.52 Permutation testing plot for the PLS-DA model shown in Figure 
3.50. Thirty-four permutations selected with reference to thirty-two cancer 
samples within the model. R2Y = 0.186 and Q2Y -0.0874 
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Cross validation of the model in Figure 3.50 performed as described 
previously produced the results displayed in Table 3-12. The resultant model 
sensitivity and specificity is shown (Table 3-13). 
Table 3-12 Cross validation of the model displayed in Figure 3.50 
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively 
Sample 
Y predicted 
 
Sample 
Y predicted 
 
Sample 
Y predicted 
Benign Cancer 
 
Benign Cancer 
 
Benign Cancer 
BU1 0.47 0.53 
 
BU17 -1.99 2.99 
 
BU31 0.72 0.28 
BU2 0.45 0.55 
 
BU19 0.75 0.25 
 
BU33 0.66 0.34 
BU5 0.67 0.33 
 
BU20 0.89 0.11 
 
BU34 0.72 0.28 
BU6 0.61 0.39 
 
BU21 0.79 0.21 
 
BU35 -0.21 1.21 
BU7 0.56 0.44 
 
BU22 0.80 0.20 
 
BU36 0.58 0.42 
BU8 0.48 0.52 
 
BU23 0.73 0.27 
 
BU37 0.76 0.24 
BU9 0.24 0.76 
 
BU24 0.80 0.20 
 
BU38 1.11 -0.11 
BU10 0.65 0.35 
 
BU25 0.56 0.44 
 
BU41 0.61 0.39 
BU11 0.83 0.17 
 
BU26 0.81 0.19 
 
BU42 1.00 0.00 
BU12 0.36 0.64 
 
BU27 0.64 0.36 
 
BU43 0.92 0.08 
BU13 0.78 0.22 
 
BU28 0.77 0.23 
 
BU44 1.02 -0.02 
BU15 0.71 0.29 
 
BU29 0.74 0.26 
 
BU45 0.21 0.79 
BU16 0.64 0.36 
 
BU30 0.72 0.28 
 
CU34 0.58 0.42 
CU1 0.12 0.88 
 
CU21 0.35 0.65 
 
CU35 0.47 0.53 
CU2 0.59 0.41 
 
CU22 0.90 0.10 
 
CU36 0.96 0.04 
CU7 0.55 0.45 
 
CU24 0.86 0.14 
 
CU37 0.96 0.04 
CU10 0.26 0.74 
 
CU25 0.80 0.20 
 
CU38 1.60 -0.60 
CU13 0.16 0.84 
 
CU26 0.02 0.98 
 
CU40 0.61 0.39 
CU14 0.55 0.45 
 
CU27 0.60 0.40 
 
CU41 0.56 0.44 
CU16 0.49 0.51 
 
CU29 0.58 0.42 
 
CU42 0.34 0.66 
CU17 0.60 0.40 
 
CU30 0.38 0.62 
 
CU43 0.60 0.40 
CU18 0.08 0.92 
 
CU31 0.57 0.43 
 
CU44 0.49 0.51 
CU19 0.41 0.59 
 
CU32 0.36 0.64 
    CU20 0.35 0.65 
 
CU33 0.00 1.00 
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Table 3-13 Model sensitivity, specificity, positive and negative predictive 
values 
  
Test 
Cancer 
Total 
Present (32) Absent (38) 
Positive True positive (15) False positive (8) 23 
Negative 
False negative 
(17) 
True negative 
(30) 
36 
 
 
% 95% C.I 
Sensitivity 46.9 29.1-65.2 
Specificity 78.9 62.7-90.4 
Positive predictive value 65.2 42.7-83.6 
Negative predictive 
value 
63.8 48.5-77.3 
 
A PLS-DA model for benign urine and cancer urine with a pre-operative 
bilirubin of greater than 40micromol/L is displayed (Figure 3.53). 
 
Figure 3.53 PLS-DA scores plot of urine data for 10 benign (green) and 10 
cancer samples with a bilirubin greater than 40micromol/L (blue). R2X (cum) 
= 0.301, R2Y (cum) = 0.388 and Q2Y (cum) = 0.227 
 
  
106 
 
Validity of the model displayed in Figure 3.53 was not confirmed through 
permutation testing with several permuted R2Y and Q2Y values lying above 
that of the original model for benign (Figure 3.54) and cancer (Figure 3.55) 
class permutation. 
 
 
Figure 3.54 Permutation testing plot for the PLS-DA model shown in Figure 
3.53. Twelve permutations selected with reference to ten benign samples 
within the model. R2Y = 0.236 and Q2Y -0.0441 
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Figure 3.55 Permutation testing plot for the PLS-DA model shown in Figure 
3.53. Twelve permutations selected with reference to ten cancer samples 
within the model. R2Y = 0.264 and Q2Y = -0.0453 
 
Cross validation of the model was performed as before and the results 
displayed in Table 3-14 and Table 3-15. 
Table 3-14 Cross validation of the model displayed in Figure 3.53 
 
*A sample was regarded as belonging to a class with a Y predicted value 
of >0.50. Green indicates correct and red incorrect classification respectively 
 
Y predict* 
  
Y predict* 
  
Y predict* 
Sample Benign Cancer 
 
Sample Benign Cancer 
 
Sample Benign Cancer 
BU6 0.57 0.43 
 
BU16 0.69 0.31 
 
BU32 -0.80 1.80 
BU10 0.67 0.33 
 
BU21 0.71 0.29 
 
BU38 0.84 0.16 
BU13 0.74 0.26 
 
BU30 0.59 0.41 
 
BU42 1.06 -0.06 
BU15 0.47 0.53 
 
CU8 0.66 0.34 
 
CU12 -0.07 1.07 
CU3 0.23 0.77 
 
CU9 0.41 0.59 
 
CU15 -2.55 3.55 
CU4 0.13 0.87 
 
CU11 0.70 0.30 
 
CU23 0.60 0.40 
CU5 0.60 0.40 
        
CU6 0.24 0.76 
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Table 3-15 Model sensitivity, specificity, positive and negative predictive 
values 
 
Test 
PDA 
Total 
Present (32) Absent (38) 
Positive True positive (6) False positive (1) 7 
Negative False negative (4) True negative (8) 12 
 
 
% 95% C.I 
Sensitivity 60 26.4-87.6 
Specificity 88.9 51.7-98.2 
Positive predictive value 85.7 42.2-97.6 
Negative predictive value 66.7 34.9-89.9 
 
4 Discussion 
 
For the purpose of this study eighty-five plasma samples were analysed by 
1H-NMR using the CPMG pulse sequence. Initial PCA analysis was 
suggestive of plasma metabolome separation between benign and malignant 
disease cohorts (Figure 3.1). Several outlying samples (CR1, CR12, CR13, 
CR20 and CR38) were identified. Patients CR1, CR13 and CR38 were all 
prescribed levothyroxine for hypothyroidism. This may be a confounding 
factor for metabonomic variation among these patients. No clear 
discrimination in the metabolome was apparent with regards to sex (Figure 
3.5). In addition no clear metabonomic variation between benign and pre-
malignant disease cohorts was identified (Figure 3.3). This is a potential 
direct result of insufficient patient recruitment within the pre-malignant arm of 
the study. The current study was not designed to evaluate the metabolome 
of patients with known pre-malignant disease. As such only five patients with 
pre-malignant disease were included within the study (diagnosed only 
following pancreatic resection for presumed malignancy). Among the five 
patients with pre-malignant disease, one patient (BR6) laid outside of the 95% 
confidence interval as an outlying sample. In order to evaluate the 
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metabolome of patients with benign versus malignant disease alone patients 
with pre-malignant disease were excluded from further analysis.  
Pre-operative plasma bilirubin accounted for significant variability in the 
metabolome among cancer patients. A cut off bilirubin of 40 micromol/L 
appeared to be significant (Figure 3.8). It is important to emphasise that 
although the pre-operative plasma bilirubin was statistically dissimilar 
between benign and cancer cohorts respectively (p 0.0007), the mean 
bilirubin among the cancer cohort was only 29.1 versus 9.3 micromol/L 
among benign patients. From a clinical standpoint a bilirubin of 29 
micromol/L is only mildly elevated and is at the lower end of that which would 
be detectable upon clinical examination. Many patients included in the 
resection arm of the study had already undergone ERCP and biliary stent 
insertion.  This implies that pre-operative samples were collected from 
patients with a clearing plasma bilirubin. If plasma samples had been 
collected prior to ERCP and stenting, the effect of bilirubin on the 
metabolome may have been more pronounced. It is therefore imperative that 
future studies document and account for plasma bilirubin in chemometric 
analysis.     
PLS-DA analysis was subsequently performed on a cohort of 34 benign and 
42 cancer samples (Figure 3.11). Validity was assessed through both 
permutation testing and cross validation techniques (section 3.1.3). Model 
sensitivity, specificity, positive and negative predictive values of 64.9, 73.5, 
72.7 and 65.8% respectively were generated through internal cross 
validation techniques (Table 3-3). Similar PLS-DA models were generated 
for benign and malignant plasma samples among a European population 
with a pre-operative plasma bilirubin of less than 40 micromol/L (Figure 3.22) 
and greater than 40 micromol/L (Figure 3.26).  
OPLS loading plots facilitated metabolite identification (Table 3-9). Up-
regulated metabolites in a state of malignancy included isobutyrate, 3-
hydroxybutyrate, lactate, acetoacetate, pyruvate, taurine and β-glucose. 
Down-regulated metabolites included VLDL, valine and acetate. Upon 
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subgroup analysis valine appeared suppressed only among non-jaundiced 
cancer patients. 3-hydroxybutyrate appeared up-regulated only among 
cancer patients with a bilirubin > 40 micromol/L. Acetoacetate was up-
regulated among cancer patients with a bilirubin > 40 but suppressed in 
those with a bilirubin < 40 micromol/L (Table 3-9). 
To date one publication compares the 1H-NMR pancreatic cancer plasma 
metabolome to that of healthy volunteers or those with chronic pancreatitis 
(130). The study is relatively small in size and included only nineteen 
pancreatic cancer patients, twenty patients with chronic pancreatitis and 
twenty healthy volunteers. VLDL, valine, 3-hydroxybutyrate and lactate were 
metabolites identified in common with this current study. In contrast to the 
current study Zhang et al. described up-regulation of VLDL along with 
suppression of LDL and HDL among pancreatic cancer subjects (when 
compared against healthy controls). VLDL was also interestingly found to be 
up-regulated among patients with chronic pancreatitis when compared 
against healthy controls. This discrepancy with the current study may be 
accounted for by the recruitment of patients with benign pancreaticobiliary 
disease (including chronic pancreatitis) to comprise the control arm of the 
current study (rather than healthy volunteers). In common with the current 
study down-regulation of valine among cancer patients was described. In 
addition I however emphasise that down regulation was only apparent 
among patients with a plasma bilirubin < 40 micromol/L in the current study. 
The described up-regulation of taurine along with glucose among 
pancreaticobiliary cancer patients was similarly described by Tesiram et al. 
who evaluated the serum metabolome of patients with pancreatic cancer in 
comparison to that of healthy volunteers (133). Up-regulation of glucose was 
similarly described by Bathe et al. who studied the serum metabolome 
pancreatic cancer along with that of patients with benign biliary disease (131).  
In contrast to the current study OuYang et al. along with Zhang et al. 
described down regulation of 3-Hydroxybutyrate among pancreatic cancer 
subjects (130, 132). In the current study 3-hydroxybutyrate appeared up-
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regulated among patients with a pre-operative bilirubin > 40 micromol/L 
although unchanged among those with a pre-operative bilirubin of < 40 
micromol/L. 
1H-NMR analysis of urine using the 1D-NOESY pulse sequence failed to 
provide statistically significant evidence of urinary metabonomic variation 
between benign and malignant pancreaticobiliary disease cohorts (section 
3.2). These findings most likely reflect the known environmental influence 
over the urinary metabolome. Lenz et al. in 2003 performed H-NMR 
metabonomic analysis on both plasma and urine obtained from a group of 12 
healthy male subjects on two separate intervals 14-days apart. Despite 
standardization of diet there was considerable inter-subject (but not intra-
subject) variability of the urinary metabolome (140). 
In conclusion I report the feasibility of differentiating the plasma 
metabonomic profile of patients with pancreaticobiliary malignancy from 
those with benign disease. Subgroup analysis in the current study failed to 
identify significant separation according to cancer cell type, resectability or 
pre-malignant disease status. I believe this is likely a reflection of patient 
recruitment rather than a true finding. Pre-operative plasma bilirubin however 
appeared to have a significant effect on the metabolome. 
To facilitate biomarker discovery for pancreatic cancer future NMR studies 
require to carefully consider and describe techniques to counteract the 
confounding effect of bilirubin on the plasma metabolome. One potential 
solution is to describe varying metabonomic profiles for a neoplastic state 
based upon the presenting bilirubin range. This clearly adds complexity to 
future clinical biomarker utilization. A second option is to identify and zero fill 
a section of the metabolome directly confounded by plasma bilirubin prior to 
chemometric analysis. A third option is to deploy the novel biomarker 
following pre-operative biliary drainage procedures or among a non-
jaundiced patient cohort. This clearly delays and limits clinical utility of the 
biomarker and would preclude its use in surgical units who perform 
pancreatic resections in patients with an obstructed biliary system. 
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Larger studies are clearly required to further define the plasma metabolome 
of pancreaticobiliary malignancy. Although it may be possible to define 
histological cell type and predict resectability, chemosenstivity or indeed 
prognosis I believe the first step is to aid in the differentiation of a malignant 
pancreaticobiliary process from that of benign disease. A combination 
strategy along with other modalities such as clinical imaging and currently 
available biomarkers such as CA 19-9 would most likely be used. To verify 
the described plasma findings and to facilitate biomarker development it 
would be useful in future studies to evaluate the metabolome at diagnosis, 
following resection and at the time of potential disease recurrence. Any 
future metabonomic profile of disease or novel biomarker model would also 
require validation with an external dataset.  
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Patient Information Sheet 1 – 27/04/2012 – Version 2 
 
Part 1: 
 
Metabolomics & Novel Biomarkers for Pancreatic Cancer (Pancreatic resection 
group) 
 
You are invited to take part in a RESEARCH study. Before you decide, it is important 
you understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Ask us if there is anything that is not 
clear, or if you would like more information. Take time to decide whether you wish to 
take part. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take part 
 
Part 2 gives you more information about the conduct of the study 
 
Thank you for reading this 
 
What is the purpose of the study? 
 
Cancer of the pancreas may be difficult to diagnose and often presents late. We aim to 
identify novel markers (biomarkers) to aid diagnosis and guide treatment. The 
markers of interest are small molecules which are released during metabolism. 
Metabolism is the set of chemical reactions that happen in the body to sustain life. We 
know that metabolism is altered in a disease state and that different products of 
metabolism are released. Our intent is to determine a signature that could be used to 
distinguish pancreatic cancer from non-cancerous conditions of the pancreas or biliary 
tree.   
 
Why have I been invited? 
 
You have been chosen for this study because you are about to undergo surgery for 
suspected pancreatic cancer. We plan to analyse a sample of your blood, bile, 
pancreatic fluid and urine for various small molecules or products of metabolism. We 
will then compare your metabolite levels with patients who have undergone an 
operation for a non-cancerous condition. We plan to include a total of 100 patients 
with cancer of the pancreas and 50 patients who have undergone an operation for a 
non-cancerous condition. 
 
Do I have to take part? 
 
It is entirely up to you if you wish to participate or not. We would like to reassure you 
that if you do not wish to participate this will not affect the standard of your care in 
any way. You are free to withdraw at any time, without giving a reason.	
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What will happen to me if I take part? 
 
If you agree to participate we will ask you to sign a consent form. During your 
operation we will withdraw 2 teaspoons of blood from a line that will have already 
been inserted for the purpose of your operation by your anaesthetist. In addition your 
operating surgeon will collect a sample of bile and pancreatic fluid, which is released 
but normally discarded during your operation. A sample of urine will be collected 
from your urine catheter bag. You will be involved in the study only on the operative 
day. 
 
What are the potential benefits of taking part? 
  
Although there are no direct benefits to you from participating in this study, it will 
provide us with important information which may be of great value to improve the 
care of future patients.  
 
What are the possible disadvantages and risks of taking part? 
 
There are no particular risks or disadvantages of taking part in this study. All your 
care will proceed as planned. Now new treatment will be added or withheld.  
 
Will my taking part be kept confidential? 
 
Yes. We follow ethical and legal practice and all the information about you will be 
handled in confidence. The details are included in Part 2. 
 
What if I have concerns? 
 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2. 
 
This completes Part 1. If the information in Part 1 has interested you and you 
are considering participation, please read the additional information in Part 2 
before making any decision. 
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Part 2: 
 
What will happen if I don’t want to carry on with the study? 
 
You are free to withdraw from the study any time you want. It would be your decision 
to allow us or not to analyse any information which we may have already obtained 
from your samples. Any stored samples identifiable as yours could be destroyed if 
you wish. 
 
What if there is a problem? 
 
If you have any concerns about this study or the way it has been organised you should 
contact the principal investigator (Mr Andrew Smith) at the address or telephone 
number below. In the unlikely event that something goes wrong and you are harmed 
during the research the normal NHS complaints mechanism will still be available to 
you.  
 
 
Principal Investigator 
 
Mr Andrew Smith  
Consultant Pancreatic & General Surgeon  
St James Institute of Oncology 
St James Hospital 
Beckett Street 
Leeds 
LS9 7TF 
(0113) 2064719 
 
Alternatively you may contact the Patient Advice and Liaison Service (PALS) at the 
Leeds Teaching Hospitals on (0113) 2067168  
 
 
Will my taking part in this study be kept confidential? 
 
We will keep all of your data strictly confidential. All of your samples for the purpose 
of research will be coded immediately after collection. No identifying information 
other than the code will be attached to your samples. The deciphering of the code to 
identify your personal details can only be done on a dedicated secure computer within 
St James Hospital by members of the research team. Any publication of the results 
will be completely anonymous.  
 
Involvement of the General Practitioner (GP) 
 
It is not necessary to inform your GP about your participation in this study 
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What will happen to any samples I give? 
 
Your samples will be stored securely within The Leeds Teaching Hospitals NHS 
Trust. Analysis will take place within the School of Chemistry at the University of 
Leeds. The samples will not be used for any other future studies. At the end of the 
study, they will be disposed of securely. No samples will be transferred outside the 
UK. 
 
Will any genetic tests be done? 
 
No. There will not be any sort of genetic tests conducted using your blood samples.  
 
What will happen to the results of the research study? 
 
The results from this study may be presented at medical meetings or published in 
medical journals. We can assure you that you will not be identifiable in any of the 
results. We regret that we cannot inform you of your individual sample analysis 
results. However, upon request we are happy to provide an overview of the findings 
of the study once it is completed.  
 
Who is organising and funding the study? 
 
The study is organised and funded by the Department of Surgery within the Leeds 
Teaching Hospitals NHS Trust. The doctors involved in the study are not being paid 
for conducting the study 
 
Who has reviewed the study? 
 
This study has been reviewed by the Northampton Research Ethics Committee.  
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Patient Information Sheet 2 – 27/04/2012– Version 2 
 
Part 1: 
 
Metabolomics & Novel Biomarkers for Pancreatic Cancer 
 (Non-Cancer control group) 
 
You are invited to take part in a RESEARCH study. Before you decide, it is important 
you understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Ask us if there is anything that is not 
clear, or if you would like more information. Take time to decide whether you wish to 
take part. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take part 
 
Part 2 gives you more information about the conduct of the study 
 
Thank you for reading this 
 
What is the purpose of the study? 
 
Cancer of the pancreas may be difficult to diagnose and often presents late. We aim to 
identify novel markers (biomarkers) to aid diagnosis and guide treatment. The 
markers of interest are small molecules which are released during metabolism. 
Metabolism is the set of chemical reactions that happen in the body to sustain life. We 
know that metabolism is altered in a disease state and that different products of 
metabolism are released. Our intent is to determine a signature that could be used to 
distinguish pancreatic cancer from non-cancerous conditions of the pancreas or biliary 
tree.   
 
Why have I been invited? 
 
You have been chosen for the study because you are about to undergo an operation 
for a non-cancerous condition of the biliary tree or pancreas. We plan to analyse a 
sample of your blood, bile and urine for various small molecules or products of 
metabolism. We will then compare your metabolite levels with patients who have 
undergone an operation for pancreatic cancer. We plan to include a total of 100 
patients with cancer of the pancreas and 50 patients who have undergone an operation 
for a non-cancerous condition. 
 
Do I have to take part? 
 
It is entirely up to you if you wish to participate or not. We would like to reassure you 
that if you do not wish to participate this will not affect the standard of your care in 
any way. You are free to withdraw at any time, without giving a reason.	
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What will happen to me if I take part? 
 
If you agree to participate we will ask you to sign a consent form. In the anaesthetic 
room we will withdraw 2 teaspoons of blood from a cannula or line that will be 
inserted for the purpose of your operation by your anaesthetist. A sample of bile will 
be aspirated from your gallbladder once it has been removed from your body. A 
sample of urine will also be collected from you prior to your operation. Your care will 
not be affected in any way by the collection of these samples. You will be involved in 
the study only on the operative day. 
 
What are the potential benefits of taking part? 
  
Although there are no direct benefits to you from participating in this study, it will 
provide us with important information which may be of great value to improve the 
care of future patients.  
 
What are the possible disadvantages and risks of taking part? 
 
There are no particular risks or disadvantages of taking part in this study. All your 
care will proceed as planned. Now new treatment will be added or withheld.  
 
Will my taking part be kept confidential? 
 
Yes. We follow ethical and legal practice and all the information about you will be 
handled in confidence. The details are included in Part 2. 
 
What if I have concerns? 
 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2. 
 
This completes Part 1. If the information in Part 1 has interested you and you 
are considering participation, please read the additional information in Part 2 
before making any decision.	
  
128 
 
 
 
 
Part 2: 
 
What will happen if I don’t want to carry on with the study? 
 
You are free to withdraw from the study any time you want. It would be your decision 
to allow us or not to analyse any information which we may have already obtained 
from your samples. Any stored samples identifiable as yours could be destroyed if 
you wish. 
 
What if there is a problem? 
 
If you have any concerns about this study or the way it has been organised you should 
contact the principal investigator (Mr Andrew Smith) at the address or telephone 
number below. In the unlikely event that something goes wrong and you are harmed 
during the research the normal NHS complaints mechanism will still be available to 
you.  
 
 
Principal Investigator 
 
Mr Andrew Smith  
Consultant Pancreatic & General Surgeon  
St James Institute of Oncology 
St James Hospital 
Beckett Street 
Leeds 
LS9 7TF 
(0113) 2064719 
 
Alternatively you may contact the Patient Advice and Liaison Service (PALS) at the 
Leeds Teaching Hospitals on (0113) 2067168  
 
Will my taking part in this study be kept confidential? 
 
We will keep all of your data strictly confidential. All of your samples for the purpose 
of research will be coded immediately after collection. No identifying information 
other than the code will be attached to your samples. The deciphering of the code to 
identify your personal details can only be done on a dedicated secure computer within 
St James Hospital by members of the research team. Any publication of the results 
will be completely anonymous.  
 
Involvement of the General Practitioner (GP) 
 
It is not necessary to inform your GP about your participation in this study	
  
129 
 
 
 
 
 
 
 
 
 
 
 
 
What will happen to any samples I give? 
 
Your samples will be stored securely within The Leeds Teaching Hospitals NHS 
Trust. Analysis will take place within the School of Chemistry at the University of 
Leeds. The samples will not be used for any other future studies. At the end of the 
study, they will be disposed of securely. No samples will be transferred outside the 
UK. 
 
Will any genetic tests be done? 
 
No. There will not be any sort of genetic tests conducted using your blood samples.  
 
What will happen to the results of the research study? 
 
The results from this study may be presented at medical meetings or published in 
medical journals. We can assure you that you will not be identifiable in any of the 
results. We regret that we cannot inform you of your individual sample analysis 
results. However, upon request we are happy to provide an overview of the findings 
of the study once it is completed.  
 
Who is organising and funding the study? 
 
The study is organised and funded by the Department of Surgery within the Leeds 
Teaching Hospitals NHS Trust. The doctors involved in the study are not being paid 
for conducting the study 
 
Who has reviewed the study? 
 
This study has been reviewed by the Northampton Research Ethics Committee. 	
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